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Autophagy refers to an evolutionarily conserved process in which intracellular 
protein aggregates and damaged organelles are engulfed in autophagosome for 
lysosomal degradation. The cholesterol-enriched specialized membrane micro-
domains (defined as lipid rafts) are known to play a crucial role in the 
assembly of signaling molecules, proteins trafficking and the balance of 
membrane fluidity. There are mainly two types of lipid rafts: the planar lipid 
rafts and Caveolae. Caveolin-1 (Cav-1) is one of the key membrane proteins in 
maintaining the structure and function of both types of lipid rafts. Currently, 
the functional role and the regulatory mechanism of Cav-1 and lipid rafts in 
autophagy remain largely elusive. The hypothesis is that the Cav-1 and lipid 
rafts modulate autophagy and via which they play important roles in cell stress 
responses and cancer development. In order to test this hypothesis, the 
following investigations were performed to study: (i) the role of Cav-1 and 
lipid rafts in autophagy at early stage; (ii) the role of Cav-1 and lipid rafts in 
autophagy at late stage; (iii) the effect of lipid rafts disruption-mediated 
autophagy in stress response and breast cancer development. 
First, in both mouse embryonic fibroblasts (MEF) and human breast cancer 
cells, it was  found that Cav-1 deficiency and disruption of lipid rafts by 
cholesterol depletion increased both basal and inducible autophagic flux. This 
effect is independent of polymerase I and transcript release factor (PTRF), one 
of the principle caveolae proteins, indicating that it is the planar lipid rafts, but 
not caveolae, play a major role in autophagy modulation. In addition, the 
induction of autophagy after lipid rafts disruption is independent of Akt-
mTOR pathway, the key negative regulator of autophagy. 
xiii 
 
Second, disruption of lipid rafts enhances the mobility of Atg16L1 vesicles, 
and promotes the Atg5-Atg12 conjugation and autophagosome formation. The 
interactions between SNARE protein VAMP7 and the autophagic proteins 
(such as Atg5 and LC3) are also increased after lipid rafts disruption, 
indicating the enhanced SNARE-mediated fusion of autophagosome precursor.  
Third, the lysosome function is enhanced by lipid rafts disruption and Cav-1 
deficiency, evidenced by (i) increased lysosomal acidification, (ii) enhanced 
lysosomal proteolysis, and (iii) increased cathepsin enzyme activity. Moreover, 
disruption of lipid rafts promotes lysosomal V-ATPase assembly, indicating 
that the enhanced V-ATPase activity is possibly responsible for the activated 
lysosome function.  
Last, cancer cells with disruption of lipid rafts by cholesterol depletion or Cav-
1 deficiency are found to be more resistance to stress such as starvation, 
indicating that the lipid rafts disruption-mediated autophagy serves as a cell 
survival mechanism. More importantly,  the down-regulated level of Cav-1, 
accompanied by enhanced autophagic level was found in human breast cancer 
cells and cancerous tissues, thus indicating a potential role of lipid rafts 
disruption-mediated autophagy in breast cancer development.  
In summary, our data have provided strong evidence that Cav-1 and lipid rafts 
are closely implicated in determining cell stress responses via regulation of 
autophagy. Understanding the function of Cav-1 and lipid rafts in autophagy 
regulation expand the functional scope of Cav-1 and lipid rafts. More 
importantly, our study provides the potential indicator for the suitability of 
using autophagy suppression as a therapeutic strategy for breast cancer 
patients with down-regulated Cav-1.  
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1.1.1. Overview of autophagy 
The term “autophagy” was coined by Christian de Duve based on his 
discovery of lysosomes (De Duve, 1963). The three major types of autophagy 
are: macroautophagy, microautophagy, and chaperon-mediated autophagy 
(CMA). Macroautophagy (referred as autophagy hereafter) refers to an 
evolutionarily well conserved process in which intracellular protein aggregates 
and damaged organelles are engulfed in autophagosome and degraded via the 
lysosomal pathway. It serves as a powerful booster of metabolic homeostasis 
by recycled the degraded contents back to cytoplasm (Choi et al., 2013; 
Mintern and Villadangos, 2012; Mizushima and Levine, 2010). 
1.1.2. The process of autophagy 
The autophagy is known to be controlled by a group of proteins encoded by 
autophagy-related-genes (Atgs) in several consecutive stages. Most of these 
genes required for autophagy are conserved from yeast to human (Choi et al., 
2013; Meijer et al., 2007; Rubinsztein et al., 2012). There are mainly two 
consecutive stages in the whole autophagy process: 1) the early stage, which is 
the process leading to the formation of autophagosome, including the 
Induction or initiation step and Nucleation/Expansion/Elongation step; 2) the 
late stage, mainly refer to the maturation/degradation step, which is 
characterized by the maturation or degradation of autophagosome contents 
after the fusion between autophagosome and late endosome/lysosome (Shen 
and Mizushima, 2014). The detailed steps are described below and illustrated 




Figure 1.1 Summary of the different stages of the autophagy process in 
mammalian cells. (Modified based on (Rubinsztein et al., 2012)). 
 
1.1.2.1. Induction or initiation 
The initiation of autophagy starts with emergence of phagophore or 
preautophagosomal structure (PAS), and which process is regulated by the 
ULK1/Atg1 complex downstream of mechanistic target of rapamycin complex 
1 (mTORC1). The mTORC1 plays a role in the regulation of cell growth and 
protein synthesis by the phosphorylation of two key translational regulators 
eukaryote initiation factor 4E-binding protein (4EBP1) and S6 kinase (S6K) 
(Jewell et al., 2013; Zoncu et al., 2011). mTOR inhibitors such as rapamycin 
are well known to induce autophagy, the detailed regulatory mechanism will 
be discussed in Section 1.1.3 and 1.1.5.  
1.1.2.2. Nucleation/Expansion/Elongation 
This process is mediated by Class III phosphatidylinositol 3-kinases (PI3K)-
Beclin-1 complex (Choi et al., 2013; Wong et al., 2011). The membrane 
binding domain of Beclin1 is proved to be important in the nucleation process 
(Huang et al., 2012). Moreover, the completion of autophagosome formation 
is controlled by two conjugation systems: Atg12-Atg5 and microtubule-
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associated protein 1 light chain3 (LC3)-phosphatidylethanolamine (PE). The 
detailed information of these two conjugation systems will be discussed in 
Section 1.1.3. 
1.1.2.3. Maturation/degradation 
This is the final step of autophagy, in which the outer membrane of the 
autophagosome fuses with a lysosome to form an autolysosome where the 
inner membrane and luminal contents are degraded via acidic lysosomal 
hydrolases (Choi et al., 2013). The detailed information of the lysosome will 
be discussed in the Section 1.1.4. 
1.1.3. Autophagy machinery 
1.1.3.1. ULK1/2 complex 
The unc-51-like kinase (ULK) 1/2 complex is responsible for the initiation 
step of autophagosome formation. ULK1/2 complex is composed by three 
major components: ULK1/2, ATG13, and FIP200 (Mizushima, 2010). ULK1 
and ULK2 are mammalian Atg proteins which appear to be most similar to 
yeast Atg1. Atg13 and FIP200 are function homolog of yeast Atg13 and 
Atg17, respectively (Mizushima, 2010). 
ULK1/2 complex is identified as a direct target of the class I PI3K-Akt-mTOR 
signaling pathway, which responses to the autophagy inducers, such as amino 
acid starvation (Hosokawa et al., 2009; Jung et al., 2009). As shown in Figure 
1.2, under full nutrients conditions, the Atg13 and ULK1/2 is phosphorylated 
by mTORC1, which inhibits the kinase activity of ULK1/2. While after 
inhibition of mTORC1 by amino acid starvation or rapamycin treatment, the 
mTORC1 is released from ULK1/2 complex. Then the ULK1/2 is activated 
and subsequently phosphorylates Atg13 and FIP200 and ULK1 itself 
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(Hosokawa et al., 2009; Jung et al., 2009). Despite phosphorylation, the 
ULK1/2 complex is also modulated by other forms of posttranslational 
modification, including acetylation. The acetyltransferase TIP60, which is 
phosphorylated by glycogen synthase kinase-3, directly acetylates and 
activates ULK1 to induce autophagy under serum-starvation (Lin et al., 2012).  
 
Figure 1.2 Model of ULK1/2 complex regulation by mTORC1 (Modified 
based on (Jin and Klionsky, 2013)). 
 
1.1.3.2. Class III PI3K-Beclin-1 complex  
Two types of PI3K, class I and class III, are found to be closely related to 
autophagy regulation in mammalian cells. While class I PI3K is known to 
negatively regulate autophagy via activation of AKT-mTOR pathway, 
(Hemmings and Restuccia, 2012) the class III PI3K is the key positive 
regulator for the nucleation stage of autophagosome formation (Backer, 2008).  
Class III PI3K, or VPS34, phosphorylates the 3-position of 
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phosphatidylinositol to produce phosphatidylinositol 3-phosphate (PI3P), 
which is required for autophagosome formation (Backer, 2008). Although 
VPS34, together with p150 are the core components of this complex, there are  
several other important proteins in this complex, such as Beclin-1, ATG14L, 
VMP-1, Bif-1 and Rubicon (Fimia et al., 2007; Matsunaga et al., 2009; 
Ropolo et al., 2007; Takahashi et al., 2007). The class III PI3K complex is 
involved in glucose starvation-induced autophagy as a downstream target of 
adenosine monophosphate–activated protein kinase (AMPK) signaling 
pathway, as well as  in amino acid deprivation-induced autophagy under the 
regulation of ULK1 kinase (Kim et al., 2013a; Russell et al., 2013).  
For glucose-starvation induced autophagy, there are different types of class III 
PI3K complexes regulated by AMPK. The first two types of class III PI3K 
complexes can be considered as the non-autophagy complex, which consist of 
VPS34 only or combined with Beclin1. The activities of these two non-
autophagy complexes are inhibited by AMPK via VPS34 phosphorylation. 
While the interaction of autophagy protein Atg14L will 'switch' these non-
autophagy complex to pro-autophagy class III PI3K complex by inhibition of 
VPS34 phosphorylation and induction of Beclin1 phosphorylation (Kim et al., 
2013a). The working model of VPS34 complex regulation by ULK on amino-
acid withdrawal also can be linked to the pro-autophagy complex, which 
containing VPS34, Beclin1 and Atg14L or UVRAG. Amino acid starvation 
inhibits mTORC1 activity and sequentially activates ULK1, which will 
enhance the activity of pro-autophagy class III complex by phosphorylating 




1.1.3.3. Two ubiquitin-like conjugation systems 
In the Nucleation/expansion/elongation step of autophagosome formation, 
there are two ubiquitin-like conjugation systems: Atg12-Atg5 system and 
LC3-PE system. These systems share identity with ubiquitin system through 
attachment to small molecules and proteins. These two interconnected 
conjugation systems are highly conserved from yeast to mammals (Jin and 




Figure 1.3 Two ubiquitin-like conjugation systems (Green and Levine, 
2014). 
 
a) Atg12-Atg5 conjugation system 
The C-terminal glycine of human Atg12 is conjugated to a lysine at residue 
130 of Atg5 through the generation of an isopeptide bond (Mizushima et al., 
1998). The Cys572 of E1-like enzyme Atg7 is required for its interaction with 
Atg12 and promotes the following interaction with E2-like enzyme Atg10 
through Cys165, which will enhance the generation of the Atg12-Atg5 
complex (Tanida et al., 2001). An E3-like enzyme autophagy-related 16-like 1 
(ATG16L), which is the homolog of yeast Atg16, was identified to associated 
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with Atg12-Atg5 conjugation, and Atg5 is required in this process (Mizushima 
et al., 2003).  
b) LC3-PE conjugation system 
LC3, the homolog to yeast Apg8, is the core machinery of the second 
ubiquitin-like conjugation system, which controls the expansion of 
autophagosome (Kaufmann et al., 2014). In this conjugation system, firstly, 
The C-terminal glycine of LC3 is exposed after the cleavage of the ultimate C-
terminal amino acid by a cysteine protease Atg4. Then the truncated LC3 
protein conjugated to PE to generate the lipidated form of LC3 (LC3-II) under 
the regulation of Atg7 and Atg3 (Jin and Klionsky, 2013). Similar to the 
Atg12-Atg5 conjugation system, Atg7 is also the E1-like enzyme for LC3-PE 
conjugation system (Tanida et al., 2001). Atg3 is identified as an E2-like 
enzyme for this conjugation system through the formation of an intermediate 
conjugate with LC3 (Tanida et al., 2002), and a membrane-curvature-sensing 
domain in Atg3 is recently found to be essential for the LC3 lipidation (Nath 
et al., 2014).  
The lipidated LC3-II is a well-identified marker for autophagy which recruits 
to both the outer and inner sides of autophagosome membrane, while the 
soluble LC3-I is distributed in the cytosol. The LC3-II distributed in the outer 
membrane of autophagosome will be deconjugated by Atg4 to recycle to the 
cytosol (Jin and Klionsky, 2013). Meanwhile, LC3-II distributed in the inner 
membrane will be degraded in the late stage of autophagy (Kimura et al., 
2007). 
In addition, a recent report used an in vitro system to establish a working 
model of the interconnection between this two conjugation systems. Firstly, 
9 
 
Atg12-Atg5 conjugation facilitates the lipidation of LC3. Then they lipidated 
LC3 directly recruits Atg12-Atg5 complex to autophagosome membranes via 
the recognization of a newly identified Atg8-interacting motif of Atg12. In 
addition, Atg16 is also involved in these processes for the ordered membrane 
scaffold assembly of autophagosome (Kaufmann et al., 2014). 
c) VAMP7 in regulation of two ubiquitin-like conjugation systems 
In addition, there is a recent report identifying a role of vesicle-associated 
membrane protein (VAMP)7 in the regulation of these two ubiquitin-like 
conjugation systems (Moreau et al., 2011). VAMP7 is a transmembrane 
protein which belongs to the SNAREs (SNAP (Soluble NSF Attachment 
Protein) REceptor) family (Fader et al., 2009). SNAREs are a superfamily of 
membrane-associated proteins, containing evolutionarily conserved stretch of 
60-70 amino acid, which is called SNARE motif (Jahn and Scheller, 2006). 
SNAREs is known as mediator of vesicular fusion events (Lang, 2007).  
In mammalian cells, the homotypic fusion of phagophore precursors (Atg16L 
positive vesicles) is known to be under the regulation of VAMP7. VAMP7 is 
required for Atg16L homotypic fusion in the initiation stage, the formation of 
Atg5-Atg16-Atg16L complex in the following nucleation stage, as well as 
binding process to LC3 (as illustrated in Figure 1.4), suggesting the role of 
SNAREs protein VAMP7 in the beginning of autophagosome formation via 
promoting the formation of the two conjugation complexes (Moreau et al., 






Figure 1.4 The model of Atg16L1 precursor maturation with the 
regulation of VAMP7 (Moreau et al., 2011). 
 
1.1.4. Lysosome 
Lysosome is the cellular organelle containing hydrolase enzymes and plays 
crucial roles in cellular clearance (Lieberman et al., 2012; Saftig and 
Klumperman, 2009). The acidic internal pH in lysosomes is generated by the 
action of a V-ATPase (Vacuolar H+-ATPase), a proton-pumping membrane 
protein and maintained by the balance of counterion channels (Mindell, 2012).  
V-ATPases are evolutionary conserved ATP-driven proton pumps which is 
composed by a membrane bound V0 subunit (which contains the proton pore) 
and a cytosolic V1 subunit (which contains the sites of ATP hydrolysis). As 
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shown in Figure 1.5, the activity of V-ATPase is regulated by reversible 
disassembly (Kane, 2012; Mindell, 2012). Although glucose deprivation is a 
known trigger for disassembly of V-ATPase, the other environmental signals 
and its regulatory mechanism of V-ATPase assembly and disassembly remain 
largely unclear. In mammalian cells, several proteins are reported to be 
involved in the regulation of V-ATPase assembly, such as regulator of the 
ATPase of vacuolar and endosomal membranes (RAVE) complex, aldolase, 
protein kinase A  and PI3K (Dames et al., 2006; Lu et al., 2001; Sautin et al., 
2005; Seol et al., 2001). In yeast model, depletion of glucose might change 
interactions of the intact complex with aldolase or alter the binding of non-
homologous domain of subunit A with V0, which promotes the dissociation of 
V-ATPase subunits (Lu et al., 2004; Shao and Forgac, 2004). Assembly of V-
ATPase subunits is drive by RAVE complex, which is capable to bind with 
free V1 subunits (Smardon et al., 2002). In mammalian cells, PI3K is required 
for glucose dependent assembly of V-ATPase (Lu et al., 2004). 
 
Figure 1.5 Model of reversible disassembly in response to glucose 




It has been well established that balfilomycin (Baf) and CQ are able to 
suppress the degradation step of autophagy via inhibiting lysosomal V-
ATPase, blockage of lysosome-autophagsosome fusion and neutralization of 
lysosomal acidification (Solomon and Lee, 2009; Yamamoto et al., 1998a). In 
addition, a recent study has demonstrated the functional activation of 
lysosome in the course of autophagy, which is a process depending on both 
mTORC1 inhibition and autophagosome-lysosome fusion (Zhou et al., 2013).  
Moreover, the membrane fusion mediator SNAREs are also known to be 
implicated in the fusion process of autophagosome and lysosome, including 
the Syntaxin 17, VTI1B and lysosome SNAREs VAMP8 (Itakura et al., 2012; 
Jiang et al., 2014). 
1.1.5. Regulatory pathways of autophagy 
As shown in Figure 1.6 below, autophagy can be stimulated by various signals, 
including energy depletion, limitation for growth factors and depletion of 
amino acids through different signaling pathways. The AMPK-mTORC1 axis 
is the critical pathway involved in autophagy regulation. Most of the 
regulatory pathways converge on this axis (Rabinowitz and White, 2010). 
In the presence of nutrients, including amino acids and growth factors, the 
lysosome distributed mTORC1 is in active status (Korolchuk et al., 2011; 
Sancak et al., 2010). It suppresses autophagosome initiation through a direct 
phosphorylation of ULK1 and Atg13, which inhibits the activity of the ULK1-
Atg13-FIP200 complex. When the mTORC1 activity is inhibited by nutrients 
deprivation or chemical inhibitors, the dephosphorylation will cause the 
release of ULK1-Atg13-FIP200 complex to induce the initiation of 
autophagosome formation (Hosokawa et al., 2009; Jung et al., 2009). 
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There are mainly three upstream pathways of mTORC1. Firstly, the class I 
PI3K-Akt signaling network is one of the key negative regulators of 
autophagy, which mainly responds to the limitation of growth factors 
(Hemmings and Restuccia, 2012). One connection in the middle of the Akt-
mTORC1 signaling is a protein complex called tuberous sclerosis complex-1, 
and -2 (TSC1-TSC2), which is a negative regulator of mTORC1 activity and 
response to low energy, oxygen and growth factor levels in cell (Inoki et al., 
2002; Ng et al., 2011; Zoncu et al., 2011). In addition to the modulation of 
Akt on mTORC1 via TSC1-TSC2 complex, the Akt itself is known to directly 
phosphorylate the proline-rich Akt substrate of 40 kDa (PRAS40) and thus 
causes the release of PRAS40 from mTORC1 complex to inhibit mTORC1 
activity (Wang et al., 2012; Wiza et al., 2012).  
Second, amino acids activate mTORC1 via mediating the formation of V-
ATPase-Ragulator-RAG complex directly, which then promotes the mTORC1 
translocation to late endosome/lysosome (Bar-Peled and Sabatini, 2014). 
Under amino acid deficient condition, Ragulator and V-ATPase are inhibited, 
while the GATOR1 (GAP activity towards Rags (Ras-related GTPases)) keeps 
RagA in an inactive GDP-bound state via its GTPase-activating protein (GAP) 
activity. The GDP-bound RagA is not sufficient to recruit mTORC1 to 
lysosome. Thus mTORC1 loses its interaction with its direct activator Rheb, 
leading to mTORC1 inactivation (Kim et al., 2008; Sancak et al., 2010). 
Third, AMPK serves as another key upstream regulator of mTORC1 , which 
responds to metabolic stresses, such as glucose deprivation (Shackelford and 
Shaw, 2009). AMPK consists of 3 subunits: α, β and γ. The γ subunit is 
capable of binding to ATP, ADP, and AMP. When the energy is limited, 
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cellular AMP is accumulated, which will cause the allosteric change of AMPK 
to promote its activity (Gowans et al., 2013). The AMP binding is also capable 
of enhancing the Liver kinase B1 (LKB1) activity. LKB1 is the main upstream 
regulator for AMPK, which activates AMPK via phosphorylation at Thr172 of 
its α subunit (Oakhill et al., 2010; Shaw et al., 2005). The energy deprivation 
is sensed by the high concentrations of AMP, which stimulates AMPK activity 
to inhibit mTORC1 activity and induce autophagic response (Laplante and 
Sabatini, 2012; Rabinowitz and White, 2010). What's more, there are recent 
reports showing a direct role of AMPK in autophagy modulation through a 
direct phosphorylation of ULK1 and Beclin1 (Egan et al., 2011; Kim et al., 
2013a; Kim et al., 2011). 
 
 




1.1.6. Biological functions of autophagy 
At present, the biological functions of autophagy have been extensively 
studied. Autophagy serves as a powerful booster of metabolic homeostasis. It 
is critical in various physiological and pathological processes, including cell 
survival, cell death, aging, immunity and cellular metabolism (Choi et al., 
2013; Mintern and Villadangos, 2012; Mizushima and Levine, 2010; 
Rubinsztein et al., 2012).  
1.1.6.1 The role of autophagy in cell survival/cell death 
At present, the role of autophagy and cell survival/cell death seemed complex. 
It is well-accepted for a pro-survival role of autophagy, while paradoxically, it 
also able to mediate cell death under certain circumstances.  
One key pro-survival mechanism of autophagy is the recycling of nutrients 
such as amino acids and fatty acids. Under nutrient deprivation condition, 
autophagy is stimulated, which will degrade cellular components to recycle 
the nutrients for cell survival  (Lum et al., 2005; Mizushima, 2007; Onodera 
and Ohsumi, 2005; Raben et al., 2008). The critical role of autophagy in pro-
survival function has been illustrated by utilizing autophagy deficient mice 
model, including Atg3, Atg5, Atg7, Atg9 and Atg16L. These autophagy 
defective mouse die on day one of birth due to starvation (Komatsu et al., 
2005; Kuma et al., 2004; Saitoh et al., 2009; Saitoh et al., 2008; Sou et al., 
2008). And the neuron-specific or T-cell specific depletion of autophagy also 
showed an increased apoptosis, which supporting the pro-survival function of 
autophagy (Hara et al., 2006; Komatsu et al., 2006; Pua et al., 2009).  
In addition, autophagy is also considered as a pro-survival mechanism via 
suppression necrotic cell death, including both necroptosis and poly-(ADP-
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ribose) polymerase (PARP)-mediated cell death (Shen and Codogno, 2012). 
For instance, autophagy is kown to protect apoptosis-deficient cells from 
necrotic cell death following ischemia (Degenhardt et al., 2006). And several 
studies indicate that the autophagy inhibits necroptosis in different cell lines, 
including L929 cells, lymphocytes or human cancer cells induced by TNFα, 
antigen stimulation or starvation (Bell et al., 2008; Farkas et al., 2011; Wu et 
al., 2008; Wu et al., 2009; Ye et al., 2011). 
However, despite a well-known function of autophagy in protecting cell death, 
the pro-death function of autophagy has also been reported. For example, 
autophagy contributes to cell death in several different tissues types, which 
contributes to Drasophila development, including salivary gland, midgut, and 
in reproductive cells (Berry and Baehrecke, 2007; Denton et al., 2010; Hou et 
al., 2008; Nezis et al., 2010).  
1.1.6.2 The role of autophagy in metabolism 
The illustration of autophagy in metabolism is shown in Figure 1.7 below. In 
eukaryotic cells, there are two major cellular degradation processes: the 
ubiquitin (Ub)-proteasome pathway and the autophagosomal-lysosomal 
pathway (Lecker et al., 2006). After acute amino acid deprivation (within 3 h), 
the homeostasis of intracellular amino acids is mainly maintained by the 
proteasome system (Vabulas and Hartl, 2005). However, after prolonged 
starvation, the autophagosomal-lysosomal pathway is known to play an 
important role in maintaining the intracellular amino acids pool, which is 
supported by the evidence of the decreased intracellular and extracellular 
amino acids after starvation in the autophagic deficient cells (Kuma et al., 
2004; Onodera and Ohsumi, 2005). The amino acids supplied by 
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autophagosomal-lysosomal degradation after starvation can be used to 
maintain the gluconeogenesis to provide glucose, which can be used as 
substrates for tricarboxylic acid (TCA) cycle to provide the energy and to 
maintain the essential protein synthesis (Lum et al., 2005; Mizushima, 2007; 
Onodera and Ohsumi, 2005; Raben et al., 2008).  
Despite the role of autophagosomal-lysosomal degradation to maintain the 
amino acids pool, autophagy is also implicated in the regulation of other types 
of nutrients, especially the lipid catabolism (Rabinowitz and White, 2010; 
Rubinsztein et al., 2012). The degradation of lipid droplets by autophagy is 
termed as lipophagy. Lipid droplets are monolayer cytosolic organelles for 
intracellular deposits of lipid esters (Singh and Cuervo, 2012). 
The role of autophagy played in breakdown of lipid droplets was firstly 
identified by the observations of an induced breakdown of lipid droplets after 
nutrients deprivation with an association with autophagic vesicles (Singh et al., 
2009a). And a marked increase of the lipid droplets number and size, together 
with increased levels of triacylglycerol and cholesterol contents, are found in 
cells with compromised autophagy in both in vivo and vitro systems (Singh et 
al., 2009a). In addition, a master regulator of lysosome biogenesis and 
autophagy, The transcription factor EB (TFEB), was also reported to activate 
lipid catabolism with an induction of lipophagy after starvation, which 
preventing the obesity induced by high-fat-diet in vivo model (Settembre et al., 
2013). Furthermore, the involvement of lipophagy is important in preventing 
metabolic disorders such as fatty liver, obesity and atherosclerosis, and insulin 
resistance (Singh et al., 2009b; Zhang et al., 2009a). These results highlight 




In addition to role of autophagy in maintaining amino acids pool and lipid 
metabolism, carbohydrates are also a kind of substrates for autophagy 
degradation, which releasing sugars, including glucose for glycolysis and the 
subsequent TCA cycle to maintain the energy homeostasis (Rabinowitz and 
White, 2010).  
Moreover, nucleosides which are degraded by autophagosomal-lysosomal 
degradation also can be used to generate new nucleic acid, or also go through 
the PPP and glycolysis pathways (Rabinowitz and White, 2010). 
 




1.1.6.3 The role of autophagy in cellular homeostasis. 
Autophagy is constitutively activated at low levels under basal conditions, 
which participates in maintaining the quality control of intracellular 
macromolecules and organelles (Mizushima, 2007). There are studies showing 
the accumulation of abnormal proteins and organelles in different tissues with 
autophagy deficiency, including liver and neural system (Hara et al., 2006; 
Komatsu et al., 2006; Komatsu et al., 2005; Nixon et al., 2005). Interestingly, 
in brain cells, the autophagy is not induced during starvation. However, the 
Atg7 deficiency also caused the accumulation of ubiquitinated proteins, 
ubiquitin-positive inclusion bodies, and deformed organelles without obvious 
alteration of proteasomal degradation, which proves the important role of 
autophagy in cellular quality control (Komatsu et al., 2006).  
In addition, despite of the function of autophagy elimination in maintaining 
quality control and cellular homeostasis, this elimination is also found to be 
important to ensure the clearance of  the cells destined to die by apoptosis, 
which will preventing the detrimental inflammatory responses during 
developmental process (Qu et al., 2007).  
Furthermore, autophagy is also important to the removal of damaged 
organelles, such as mitochondria, ER and peroxisome (Liu et al., 2014a; 
Nazarko, 2014). For instance, the dysfunctional mitochondria is reported to be 
selectively eliminated by autophagy, which terms as mitophagy (Wang and 
Klionsky, 2011). This selective autophagy recognizes mitochondria through 
several different ways. For example, in mammalian system, the mitochondria 
cargo receptors, such as NIX/BNIP3L, BNIP3 and FUNDC1, locates at the 
outer membrane of mitochondria and activates mitophagy through a direct 
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interaction with LC3 (Liu et al., 2012; Liu et al., 2014a; Schweers et al., 2007). 
And it has been shown recently that the reversible protein phosphorylation is 
critical in these receptor-mediated mitophagy. The Src kinase and Casein 
kinase 2 (CK2) are reported to be involved in this process (Chen et al., 2014a; 
Liu et al., 2012). In addition to phosphorylation, the ubiquitination is another 
post-transcriptional modification involved in mitophagy and other selective 
autophagy for organelle removal (Liu et al., 2014a). A potent E3 ligase Parkin 
is reported to ubiquitinates several mitochondrial proteins, including 
mitochondrial fusion mediators mitofusins. Then the ubiquitinated mitofusins 
go through proteasomal degradation and induce the mitochondrial 
fragmentation and following mitophagy (Gegg et al., 2010; Liu et al., 2014a). 
In addition, phosphatase and tensin homolog (PTEN)-induced putative kinase 
1 (PINK1) is also known to be involved in the Parkin-induced mitophagy 
(Vives-Bauza et al., 2010). 
1.1.7. Implication of autophagy in human diseases 
Accumulating evidence has highlighted the importance of autophagy in many 
human diseases, such as cancer, neurodegenerative diseases and metabolic 
disorders (Choi et al., 2013; Meijer and Codogno, 2009; Wong et al., 2011). 
Therefore, understanding the mechanisms of autophagy regulation will lead to 
discovery of novel strategies for disease control. 
1.1.7.1. Autophagy and metabolic disorders 
As what has been discussed in Section 1.1.5, one of the main functions of 
autophagy is to provide free fatty acids for oxidation in mitochondria 
(Rabinowitz and White, 2010; Rubinsztein et al., 2012). Thus, autophagy is 
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closely implicated in the pathogenesis of metabolic disorders such as diabetes 
and obesity. 
First, there are findings indicating a critical role of autophagy in supporting 
development and differentiation of adipocyte (Stienstra et al., 2014). For 
instance, Atg5 and Atg7 are reported to be required for white adipocyte cell 
differentiation and a smaller white adipose tissue were also found in Atg7 KO 
mouse model (Baerga et al., 2009; Singh et al., 2009b; Zhang et al., 2009b). 
Adipogenesis was also found to be impaired by skeletal muscle-specific 
deletion of Atg7 (Kim et al., 2013b). However, although there is a study 
showing the positive regulatory role of autophagy in supporting the stability of 
peroxisome proliferator-activated receptor (PPAR)γ2, which is the master 
regulator of adipocyte differentiation and adipogenesis (Zhang et al., 2013), 
the mechanism underlying the function of autophagy in adipocyte 
differentiation remains unclear.  
Second, autophagy in hepatocytes also plays an important role in obesity and 
diabetes. On one hand, lipid accumulation in liver was found in the mouse 
with hepatocyte-specific deficiency of Vps34 or TFEB, which both are critical 
for autophagy process (Jaber et al., 2012; Settembre et al., 2013). In addition, 
a decreased hepatic autophagy is found in both dietary and genetic mouse 
model of obesity (Yang et al., 2010). All of such evidence indicates a positive 
role of autophagy in protection from obesity. On the other hand, in the mice 
lacking hepatic Atg7 or FIP200, the lipid accumulation is decreased, which 
indicating that hepatic autophagy may maintain lipid accumulation (Kim et al., 
2013b; Ma et al., 2013a). The exact reasons underlying such a discrepancy 
remain to be further studied. 
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Third, despite the tissue specific effect of autophagy in obesity protection, 
autophagy is also reported to be involved in the whole-body metabolism, 
supported by the evidence that the systemic administration of autophagy 
inhibitor CQ prevents the high-fat diet-induced obesity (Zhang et al., 2013). 
Another good example of the functional autophagy in control of whole-body 
metabolism is autophagy in hypothalamus. Hypothalamus is the center of 
whole-body metabolism by regulation of appetite and energy expenditure, and 
plays a role in the pathophysiology of obesity and diabetes (Williams, 2012). 
Starvation-induced hypothalamic autophagy is capable of increasing the food 
intake in mouse model, thus, inhibition of hypothalamic autophagy led to 
decrease of food intake and body weight loss (Kaushik et al., 2011). In 
addition, specific depletion of Atg7 in hypothalamus is able to promote 
obesity by enhancing hypothalamic inflammation, impairing leptin-induced 
signal transduction, and decreasing α-melanocyte-stimulating hormone (Meng 
and Cai, 2011). Altogether, the hypothalamic autophagy plays an important 
role in preventing obesity through the control of hypothalamic function. 
1.1.7.2. Autophagy in cancer 
The role of autophagy in cancer is paradoxical and also remains highly 
controversial. On one hand, autophagy is believed to have anti-tumorigenesis 
function (Ding et al., 2008; Liang et al., 1999; Qu et al., 2003; Yue et al., 
2003). On the other hand, there is accumulating evidence demonstrating that 
autophagy is required for cancer promotion and progression (Kimura et al., 
2013; White, 2012; White and DiPaola, 2009). The possible explanation of the 
paradox of autophagy in cancer is the different role of autophagy played in 
different stages of cancer development. Therefore, it is widely believed that 
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autophagy is the double-edged sword in cancer (Kimura et al., 2013; White, 
2012; White and DiPaola, 2009). 
a) Autophagy suppresses initiation stage of tumorigenesis 
During the initiation stage of tumorigenesis and oncogenic transformation 
processes, autophagy functions as a tumor suppressor mechanism. Depletion 
of one of the autophagy essential gene Beclin1 is known to be related to 
tumorigenesis in various tissues, including breast tumor, lymphoma and 
hepatocellular carcinoma (Ding et al., 2008; Liang et al., 1999; Qu et al., 2003; 
Yue et al., 2003). And the systemic mosaic deletion of Atg5 and liver-specific 
deletion of Atg7 also induce benign liver adenomas (Takamura et al., 2011). 
These studies support a suppressive role of autophagy in tumorigenesis, and 
the possible mechanism is the positive role of autophagy played in preventing 
cell damage and maintaining genome stability (Guo et al., 2013b; Mathew et 
al., 2007). Firstly, by recycling nucleotides, autophagy can be considered as a 
potential supplier for DNA repair and replication (Rabinowitz and White, 
2010). Secondly, as we discussed in section 1.1.5, autophagy is known to play 
a critical role in cellular control of organelles and proteins (Liu et al., 2014a; 
Nazarko, 2014). This function enables autophagy to mitigate genotoxic stress 
by removing damaged organelles and proteins, such as mitochondria, which is 
an important source of reactive oxygen species (ROS). Atg genes deficiency is 
known to induce aberrant ROS and gene instability via accumulation of 
defective mitochondria (Mathew et al., 2009; Mathew et al., 2007). In addition, 
deficiency of autophagy is also known to cause the accumulation of damaged 
proteins, including p62, whose abnormal accumulation will induce chronic 
tissue damage and inflammation and involve in the tumorigenesis of benign 
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liver hepatomas (Komatsu et al., 2010; Mathew et al., 2009; Takamura et al., 
2011). And p62 is also plays a role in antioxidant defense via activation of 
nuclear factor erythroid 2-related factor 2 (Nrf2), which is a transcription 
factor inducing the transcription of antioxidant-defense genes (Komatsu et al., 
2010; Lau et al., 2010; Pankiv et al., 2007). Altogether, mounting evidence 
indicate a suppressive effect of autophagy in the initiation stage of tumor 
development, but whether the existing tumor will use the anti-genotoxic 
advantages provided by autophagy in the development stage remains to be 
further discussed. 
b) Autophagy enhances promotion/progression stage of tumorigenesis 
Once the tumor is formed, autophagy is known to be a cancer promoter during 
later stage (Kimura et al., 2013; White, 2012; White and DiPaola, 2009). One 
of the mechanisms underlying the promoting role of autophagy in cancer 
development is the survival advantage provided by autophagy to help cancer 
cells against nutrient starvation and other stress factors during tumor 
advancement (White, 2012). Mounting evidence indicates the pro-survival and 
proliferation function of autophagy under deprivation of amino acids, serum or 
growth factors (Boya et al., 2005; Lum et al., 2005; Mizushima, 2007; 
Onodera and Ohsumi, 2005; Raben et al., 2008). For instance, autophagy is 
known to be required for Ras-driven tumor cell proliferation and 
tumorigenesis through a distinct function in metabolism (Guo et al., 2011; 
Guo et al., 2013a). 
The observations of increased cell death in hypoxic tumor region caused by 
autophagy deficiency indicate the anti-hypoxia function of autophagy in tumor 
cells, especially for the RAS-driven cancers (Degenhardt et al., 2006; Guo et 
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al., 2011; Karantza-Wadsworth et al., 2007; Yang et al., 2011). Thus, tumor 
can use autophagy as a survival pathway against metabolic stress during the 
developing stage. In lung cancer, the observations of reduced progression from 
adenomas to adenocarcinomas after both Atg5 and Atg7 deletion also support 
the tumor promoting role of autophagy in promotion/progression stage of 
tumorigenesis (Rao et al., 2014; Strohecker et al., 2013).  
Systemic deletion of Atg4C is reported to increase susceptibility to a chemical 
carcinogen methylcholanthrene (MCA)-induced fibrosarcomas, indicating a 
suppressive role of autophagy in chemical tumorigenesis (Marino et al., 2007). 
In addition, the advantages provided by autophagy in normal tissues where can 
be used to prevent tumorigenesis, including cellular control and maintaining 
genome stability, also can be used by tumor cells in developmental stage (Guo 
et al., 2011; Valentin-Vega et al., 2012; Wei et al., 2011; Yang et al., 2011).  
Therefore, suppression of autophagy using chemical inhibitors becomes one 
novel approach in cancer therapy, including combinational therapy with 
established therapeutic agents (Kimmelman, 2011; Kimura et al., 2013; 
Maycotte and Thorburn, 2011; Notte et al., 2011). Such a notion has been 
supported by numerous studies using both in vitro cell culture and in vivo 
animal models. Currently there are quite a number of clinical trials using the 
lysosome-autophagy inhibitor CQ or hydroxychloroquine (HCQ), either alone 
or in combination therapy, in a number of cancers treatment (Poklepovic and 
Gewirtz, 2014). Results from these trials will provide the much-needed 
clinical evidence to demonstrate the usefulness of such a novel strategy in 
cancer therapy by suppression of autophagy. One potential issue is that so far 
there are no clear clinical indicators or biomarkers for the suitability of cancers 
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for autophagy inhibition. Therefore, it is believed that identification of such 
indicators will be directly beneficial for development of novel cancer 
therapeutic approaches by suppression of autophagy.  
c) Autophagy in breast cancer 
In line with the paradoxical role of autophagy in cancer as discussed above, 
similar trend is also found in breast cancer. On one hand, deficiency of 
autophagy is reported to promote the occurrence of breast cancer (Karantza-
Wadsworth et al., 2007; Liang et al., 1999; Mathew et al., 2007; Qu et al., 
2003). On the other hand, recent studies have suggested a pro-survival effect 
of autophagy in assisting the breast cancer cells to endure adverse 
environmental conditions (Boyer-Guittaut et al., 2014; Cheng et al., 2014; 
Tran et al., 2014). For instance, autophagy maintains the cellular homeostasis 
in breast cancer cells by degrading ubiquitinated proteins, decreasing ER 
stress and maintaining mitochondrial homeostasis (Boyer-Guittaut et al., 2014; 
Cheng et al., 2014; Tran et al., 2014). Autophagy inhibition by 3-
methyladenine (3-MA) or depletion by Atg7 deficiency promotes apoptosis 
and causes cell cycle arrest after glucose deprivation in human breast cancer 
cells, suggesting the pro-survival function of autophagy in breast cancer (Liu 
et al., 2014b; Tran et al., 2014). Moreover, autophagy is also considered as a 
positive regulator of epithelial-mesenchymal transition in triple negative breast 
cancer, indicating a role of autophagy in breast cancer metastasis (Chen et al., 
2014c). Consistently, autophagy is also involved in adiponectin-induced breast 
cancer metastasis (Libby et al., 2014). In addition, Beclin-1 and autophagy is 
known to be critical for tumorigenicity of breast cancer stem-like/progenitor 
cells (Gong et al., 2013). Ablation of FIP200, a key component in the ULK1 
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complex, is reported to suppress mammary tumor at both initiation and 
progression (Wei et al., 2011).  
Autophagy is also an important regulator involved in breast tumor 
microenvironment. By using the immortalized fibroblast and breast cancer cell 
co-culture system, autophagy level was shown to be up-regulated in the 
cancer-associated fibroblasts via the increased oxidative stress induced by 
breast cancer cells (Martinez-Outschoorn et al., 2010; Martinez-Outschoorn et 
al., 2011). Thus, it is possible that the induced autophagy in the cancer-
associated fibroblasts produces more energy and nutrients to support breast 
tumor development (Martinez-Outschoorn et al., 2010; Martinez-Outschoorn 
et al., 2011; Pavlides et al., 2010).  
Based on the strong evidence that autophagy plays a critical role in supporting 
breast cancer development, as discussed above, therefore, the combination of 
autophagy inhibitors with other anti-cancer therapeutic agents is considered as 
a novel strategy for breast cancer treatment. A number of studies have 
confirmed the enhancing effect of autophagy inhibitors in breast cancer 
therapeutic response, especially for triple negative breast cancer cells (Chen et 
al., 2014b; Chen et al., 2014c; Chittaranjan et al., 2014; Cook et al., 2014; 
Tran et al., 2014; Xu et al., 2014).   
1.2. LIPID RAFTS AND CAV-1 
1.2.1 Lipid rafts 
1.2.1.1. Overview of lipid rafts 
In the classic 'fluid mosaic model' of the plasma membrane developed by 
Singer and Nichols in 1972, the continuous and homogenous fluid lipid 
membrane is considered as a sea in which a mosaic of proteins floats (Singer 
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and Nicolson, 1972). However, there are an increasing number of high-
resolution structures and an abundance of functional data indicating a more 
mosaic membrane structure than fluid (Engelman, 2005; Sonnino and Prinetti, 
2013). One of the major modifications of this model is the concept of 'lipid 
rafts'.  
Lipid rafts are liquid-ordered micro-domains (10-200nm) which are enriched 
with a characteristic structural composition (sphingolipids, cholesterol and 
saturated phospholipids) in plasma and intracellular membranes of various 
organelles, including Golgi, ER, mitochondria and endosome/lysosome 
(Figure 1.8) (Lingwood and Simons, 2010; Sonnino and Prinetti, 2013; 
Waheed and Freed, 2010).  
Cholesterol, as a major lipid component of lipid rafts, is known to interact 
with saturated, high-melting phospho- and sphingolipids preferably, which 
provides the 'liquid-ordered' structure for lipid rafts (Kabouridis et al., 2000; 
Lawrence et al., 2003; Silvius, 2003; Westover et al., 2003). Sphingolipid is 
another main lipid component of lipid rafts, which associates with each other 
via their head groups (Quinn, 2010; Reeves et al., 2012). A high proportion of 
sphingolipids with mainly long-chain (22-26C) hydroxylated fatty acids is 
found in lipid rafts. These lipids are known to maintain the interdigitation of 
long-chain fatty acids across the bilayer mid-plane to couple the two 
membrane leaflets in rafts domains, which is stabilized by its interaction with 
cholesterol (Klemm et al., 2009; Veiga et al., 2001). In addition to the 
characteristic lipid composition of lipid rafts, these domains also contain 
specific groups of proteins, including caveolins (to be discussed in Section 
1.2.2), flotillins, annexins, glycosylphosphatidyl-inositol (GPI)-like proteins, 
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as well as cholesterol binding proteins (Babiychuk et al., 2002; Lingwood and 
Simons, 2010; Schuck and Simons, 2004). 
Lipid rafts are resistant to solubilization by non-ionic detergents because of 
their tight packing. The tighter packing is due to a higher enrichment of 
saturated hydrocarbon chains in sphingolipids and phospholipids in the lipid 
rafts region (Rajendran and Simons, 2005a). Thus, detergent resistant isolation 
is a well-established method for lipid rafts fractionation, which is considered 
as a major tool in lipid rafts studies (Chamberlain, 2004).  
 
 
Figure 1.8 A simplified model of lipid rafts in cell membrane (Dart, 2010). 
 
1.2.1.2. Classification of lipid rafts 
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There are mainly two types of lipid rafts existing in mammalian cells: planar 
lipid rafts and caveolae (Figure 1.8). They are defined based on their size, 
morphology and contents (Allen et al., 2007). These two microdomains have 
both overlapping and specific functions (Reeves et al., 2012).  
Caveolae, a flask-shaped membrane lipid microdomains which contains 
oligomerized caveolins, is considered as a specialized type of lipid rafts 
usually presenting in the plasma membrane (Levental et al., 2010; Sotgia et al., 
2012). They are known to be abundant in terminally differentiated cells, 
including adipocytes, endothelial cells, fibroblasts and muscle cells (Nassar et 
al., 2013). The caveolae structure is in 25-100 nm in diameter , and it was first 
observed in 1950s (Palade, 1953; Yamada, 1955). Caveolae are reported to 
function in endosytosis, signal transduction, membrane and lipid trafficking 
(Parton and del Pozo, 2013). The assembly of caveolae requires two proteins: 
Cav-1 and PTRF (Liu et al., 2008; Nassar et al., 2013). Cav-1 is the principle 
structure proteins for caveolae (Nassar et al., 2013). Without PTRF, the 
caveolae formation is disrupted and the Cav-1 is found in non-caveolae 
membrane structures (Hill et al., 2008; Mundy et al., 2012; Nassar et al., 2013). 
On the other hand, planar lipid rafts, which are also called non-caveolar lipid 
rafts, are essentially continuous without distinguishing morphological features. 
Planar rafts share a similar cholesterol and sphingolipids enriched composition 
as caveolae, but contain less Cav-1 (Wang and Paller, 2006). There are studies 
supporting the concept of planar lipid rafts by identifying the distribution of 
lipid rafts structure in the intracellular membrane system and the function 
independent of caveolae in endocytosis and cellular signaling transduction 
(Lingwood and Simons, 2010; Moon et al., 2014; Nicolau et al., 2006; 
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Sonnino and Prinetti, 2013; Waheed and Freed, 2010). However, given the 
difficulty in separating caveolae and non-caveolar rafts and visualizing these 
relative small size rafts, as well as the limitation of specific marker, the exact 
molecular mechanism of the function and regulation of planar rafts still need 
to be further explored.  
1.2.1.3. Biological functions of lipid rafts 
The lipid rafts are dynamic membrane structures with heterogeneous and 
dynamic makeup, which enable them to be involved in a wide array of 
functions including cellular signaling transduction, cytoskeletal organization, 
membrane trafficking in the whole membrane system (George and Wu, 2012; 
Levental et al., 2010; Lingwood et al., 2009; Staubach and Hanisch, 2011).  
First, lipid rafts play a central role in signal transduction via the residence of 
various important receptors, such as ionotropic receptors, G-protein-coupled 
receptors (GPCR), epidermal growth factor receptor (EGFR), as well as 
apoptosis stimulating fragment (Fas) receptor (Allen et al., 2007; George and 
Wu, 2012; Jin et al., 2008; Kaizuka et al., 2007; Monastyrskaya et al., 2005; 
Pucadyil and Chattopadhyay, 2004; Rao-Bindal et al., 2012; Wang and Yu, 
2013).  
Second, in addition to receptor proteins as mentioned above, a number of 
proteins are known to present in the lipid rafts fraction, indicating the critical 
role of lipid rafts in different cellular processes, such as ion homeostasis, 
lysosome proton balance and a number of serine/threonine 
kinases/phosphatases cascades (Dart, 2010; Thomas et al., 2014). In addition, 
it is important to note that some of the proteins which are important for 
autophagy regulation are also within lipid rafts domain. One example is Akt, 
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which acts upstream of a key negative regulator of autophagy, mTOR (Calay 
et al., 2010; Fraldi et al., 2010; Grider et al., 2009; Puri and Roche, 2006). 
Other examples include SNAREs, which are recently found to mediate 
autophagosome formation and autophagosome-lysosome fusion; as well as 
lysosomal V-ATPase, which maintains the acidic environment of lysosomes 
(Foster et al., 2003; Kaushik et al., 2006; Lafourcade et al., 2008; Yoshinaka 
et al., 2004). A very recent report identified the association of V-ATPase-
Ragulator-AXIN/LKB1-AMPK complex with the late endosome/lysosome 
lipid rafts domain, functioning as the sensor for energy stress (Zhang et al., 
2014).  
Third, membrane trafficking, including  ER-to-Golgi, post-Golgi trafficking 
and endosytosis, is another well-established function of lipid rafts in both 
caveolae-dependent and- independent ways (Lajoie and Nabi, 2010; Rajendran 
and Simons, 2005b).  
It is important to note that lipid rafts can regulate the signal transduction 
pathways both positively or negatively. On one hand, there is evidence 
indicating a more preferable affinity of oligomerized proteins to lipid rafts 
domains than the monomer proteins (Fraldi et al., 2010; Harder et al., 1998; 
Pajak et al., 2008). The clustering caused by lipid rafts most likely facilitates 
the initiation of signal transductions or assembly of the receptor and their 
adaptor proteins (Pajak et al., 2008). On the other hand, the spatial separation 
of lipid rafts residential proteins may provide protection from interaction with 
non-rafts contents, such as enzymes or its adaptor proteins (Pajak et al., 2008). 
Thus, the lipid rafts might play an inhibitory effect on some signal 
transduction pathways (Lim and Yin, 2005). Therefore, the exact functions of 
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lipid rafts on signal transduction are believed to be context-dependent. 
1.2.2 Caveolin-1 
1.2.2.1. Overview of Caveolin-1 
Cav-1 belongs to the membrane-bound scaffolding proteins family caveolins 
which is critical for structure and function of both caveolae and planar lipid 
rafts (Sotgia et al., 2012) (Figure 1.8). Cav-1 was first discovered as a 
phospho-protein in Rous sarcoma transformed cells (Glenney, 1989), which is 
a principal scaffolding protein of a major subtype of lipid rafts, caveolae 
(Boscher and Nabi, 2012; Parton and Simons, 2007). Cav-1 is evolutionarily 
conserved from worms to mammals, indicating a crucial role in cellular 
process. It has been reported to be involved in the regulation of lipid transport, 
membrane traffic and signal transduction (Bosch et al., 2011; Frank et al., 
2006; Galbiati et al., 2001; Parton and del Pozo, 2013; Sonnino and Prinetti, 
2009).  
This 22 kDa protein contains 178 amino acids with a unique hydrophobic end 
(Glenney, 1992). A very important domain for the functional Cav-1 is the 
scaffolding domain, which is a 20 amino acids domain at the amino terminus 
end (as shown in Figure 1.9) (Couet et al., 1997). This scaffolding domain is 
considered to have suppressive effect on its binding proteins (Reeves et al., 
2012). For example, the nitric oxide synthase is known to stay in inactive 
conformation when binding to Cav-1 (Feron et al., 1998). In contrast, there is 
also contrasting evidence showing a positive regulatory role of Cav-1 scaffold 
binding on the partner proteins (Wary et al., 1998; Yamamoto et al., 1998b). 
For instance, the interaction between Cav-1 and the tyrosine kinase Fyn is 
required for its function in integrin signaling and anchorage-dependent cell 
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growth. (Wary et al., 1998). Thus, the exact effect of the Cav-1 interaction 
should be carefully confirmed in different signal pathways.  
 
Figure 1.9 Primary structure and topology of Cav-1 (Modified based on 
(Williams and Lisanti, 2004)). 
 
1.2.2.2. Cav-1 and Caveolae 
Cav-1 was shown to be a structural component of caveolae, which decorates 
the cytoplasmic coat of caveolae (Williams and Lisanti, 2004). Cav-1 is the 
major structural protein of Caveolae (Nassar et al., 2013). In addition, since 
cholesterol is also a major components of caveolae, the caveolin-cholesterol 
interactions is shown to drive caveolae formation in Golgi complex (Parton et 
al., 2006). In addition, the structurure of Cav-1 in caveolae is known to be 
stabilized by PTRF (Inder et al., 2012; Nassar et al., 2013). 
1.2.2.3. Cav-1 and planar lipid rafts 
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At present, the critical role of Cav-1 in caveolae is well-studied, while there is 
accumulating evidence suggesting the importance of Cav-1 in planar lipid rafts. 
For instance, Cav-1 has been found to play an important role in lipids 
trafficking and homeostasis, including cholesterol, whose depletion will 
disrupt planar lipid rafts directly (Bosch et al., 2011; Le Lay et al., 2009). 
Moreover, genetic depletion of Cav-1 is known to reduce free cholesterol 
synthesis (Frank et al., 2006). In addition, comparing to the limited 
distribution of caveolae on plasma membrane (Levental et al., 2010), Cav-1 
has a more extensive membrane distribution in the intracellular membrane 
structures, including mitochondria, endoplasmic reticulum, as well as the late 
endosome/lysosome, indicating the existence of caveolae-independent 
function of Cav-1 in the intracellular membrane system (Mundy et al., 2012; 
Robenek et al., 2004; Schlegel et al., 2001). 
 
1.3. LIPID RAFTS AND CAV-1 IN AUTOPHAGY 
1.3.1. Lipid rafts in autophagy 
So far, the regulatory role of lipid rafts in autophagy has not been directly 
studied. There are several clues indicating a potential role of lipid rafts in 
autophagic process. Most of these studies are related to the most critical 
component of lipid rafts, cholesterol; and the results generally indicate a 
suppressive role of lipid rafts and cholesterol in autophagy regulation. At the 
autophagy initiation stage, lipid rafts are reported to positively regulate AKT 
activity which is upstream of the key negative autophagy regulator mTOR 
(Calay et al., 2010; Grider et al., 2009). Depletion of cholesterol by different 
drugs including MBCD or using lipoprotein deficient medium is found to 
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induce autophagy via suppression of Akt-mTOR pathway (Cheng et al., 2006). 
And a recent study reported that glucose starvation is capable of inducing the 
accumulation of active AMPK and disassociation of mTORC1 from lipid rafts 
fraction, leading to suppression of mTORC1 activity (Zhang et al., 2014).  
Moreover, the lipid rafts are also known to regulate membrane fusion mediator 
SNAREs which are essential for autophagosome formation and lysosome-
autophagosome fusion (Fraldi et al., 2010; Itakura et al., 2012; Lang, 2007; 
Moreau et al., 2011; Takats et al., 2013), although the exact mechanisms 
underlying the regulatory effects of lipid rafts on SNAREs are still elusive. 
One possibility is that the highly enrichment of SNAREs in lipid rafts domains. 
SNAREs are required for mediating efficient fusion of endocytosis, which 
indicates a positive role of lipid rafts in promoting SNAREs activity and 
autophagy (Lang et al., 2001; Puri and Roche, 2006). In contrast, there is 
evidence suggesting the opposite: lipid rafts and cholesterol may suppress the 
autophagosome-lysosome fusion process mediated by SNAREs (Fraldi et al., 
2010). Furthermore, in the late stage of autophagy, lipid rafts are linked to 
lysosomal function, based on evidence that some important lysosome 
membrane proteins such as V-ATPase, chloride channels CLC6/7 and 
lysosome associated membrane protein type 2A (LAMP-2A) are associated 
with lipid rafts (Foster et al., 2003; Kaushik et al., 2006; Lafourcade et al., 
2008; Yoshinaka et al., 2004). Accumulation of lysosome cholesterol by an 
intra-cellular cholesterol transport inhibitor U18666A is reported to impair 
lysosomal V-ATPase assembly and activity (Lafourcade et al., 2008). 
Consistently, the lysosome dysfunction in a lipid storage disorder, Niemann-
Pick Type C (NPC), is also related to aberrant cholesterol accumulation in 
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lysosomal membrane (Liao et al., 2007b).  
Altogether, the above-mentioned evidence generally suggests an inhibitory 
function of lipid rafts and its main components cholesterol in autophagy 
regulation. However, there are also studies indicating a positive role of lipid 
rafts in autophagy regulation. For instance, it has been reported that the 
cholesterol depletion drug MBCD is able to impair the V-ATPase activities on 
the isolated lysosome membrane (Ryu et al., 2010; Yoshinaka et al., 2004). 
Consistently, depletion of cholesterol from the isolated autophagosomes and 
lysosomes is also proved to inhibit the autophagic vesicles fusion (Koga et al., 
2010). In addition, studies of a NPC disorders also demonstrate that with an 
accumulation of cholesterol and sphingolipid caused by NPC1 deficiency, an 
increased autophagy was observed in neurons through an increase expression 
of Beclin-1, suggesting a promoting function of cholesterol in autophagy 
(Pacheco et al., 2007; Pacheco and Lieberman, 2007). Furthermore, in 
addition to cholesterol, other components of lipid rafts were also reported to 
be involved in autophagy. For example, a paradigmatic component of lipid 
rafts, GD3 ganglioside, is able to up-regulate autophagosome formation 
(Matarrese et al., 2014). One of the shpingolipids, ceramides, are also known 
to be required for autophagy induction via blockage of Akt activation, 
upregulation of Beclin-1 or suppression of nutrient transporter expression 
(Peralta and Edinger, 2009; Scarlatti et al., 2004; Schubert et al., 2000). 
However, these studies did not provide the direct evidence to show that the 
regulatory function of those lipids is achieved via lipid rafts. It remains to be 
further determined whether these individual components of lipid rafts act 
through lipid rafts per se in regulation of autophagy.  
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In a summary, due to the dynamic nature and the complex composition of lipid 
rafts, the function of lipid rafts in autophagy modulation is complicated and 
remains to be further investigated.  
1.3.2. Cav-1 in autophagy 
Several recent studies have now shown the direct role of Cav-1 in autophagy 
regulation. First, Cav-1 was reported to be interacted with the autophagic 
protein LC-3B and suppress cigarette smoke extract-induced autophagy in 
lung in vivo (Chen et al., 2010). Second, Cav-1 deficiency is able to induce 
autophagy in adipocytes via suppression of insulin and lipolytic responses (Le 
Lay et al., 2010). Third, loss of Cav-1 is able to promote autophagy under 
hypoxia and oxidative stress in adipocytes and fibroblasts (Martinez-
Outschoorn et al., 2010; Martinez-Outschoorn et al., 2011). Interestingly, a 
recent study reveals a competitive interaction between Cav-1 and Atg12-Atg5 
complex, through which it suppresses autophagosome formation mediated by 
Atg12-Atg5 complex (Chen et al., 2014d).  
However, these studies did not provide the evidence whether involvement of 
lipid rafts in the autophagy modulation is mediated Cav-1. As what has been 
discussed in Section 1.2.2 earlier, Cav-1 is known to play a critical role in 
cholesterol homeostasis and lipid rafts formation. Thus, Cav-1 might modulate 
autophagy via lipid rafts or cholesterol via the pathways which has been 
discussed in Section 1.2.3. Further studies should be performed to confirm 
whether the Cav-1 function on autophagy is lipid rafts dependent. At present, 
it is believed that Cav-1 plays a negative role in autophagy process, while the 
molecular mechanisms underlying the suppressive function of Cav-1 on 
autophagy remains to be further studied. 
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1.4. LIPID RAFTS AND CAV-1 IN CANCER  
1.4.1. Lipid rafts in cancer cell death and progression 
Importantly, lipid rafts play a very complex role in tumorigenesis, due to their 
vast varieties of biological functions. First, death receptors such as Fas and 
TNF-related apoptosis-inducing ligand (TRAIL) are known to present in lipid 
rafts, and their activation will induce programmed cell death (Gajate and 
Mollinedo, 2005; Mérino et al., 2006; Pajak et al., 2008). Second, lipid rafts 
are also critical for the activation of several pro-apoptotic protein kinases, 
including Src family kinases, c-Jun N-terminal kinase and protein kinase C 
(PKC) (George and Wu, 2012). Therefore, lipid rafts are considered as a 
positive regulator for cell death induced by cancer therapeutics (Pajak et al., 
2008). Consistently, several anti-cancer drugs, such as Edelfosine, Avicin D 
and Resveratrol, have been shown to induce apoptosis via alteration of Fas-
enriched lipid rafts (Gajate and Mollinedo, 2007; George and Wu, 2012; Reis-
Sobreiro et al., 2009; Xu et al., 2009). In addition, targeting lipid rafts may 
promote the internalization of some oncogenic proteins, such as IGF, HER2 
and EGFR (Chinni et al., 2008; Freeman et al., 2007; Lee et al., 2014; Manes 
et al., 1999). 
In contrast to the pro-death function, lipid rafts are also involved in promoting 
tumor progression by mediating the signal transduction pathways which are 
critical to maintain cell proliferation, differentiation, survival, such as Akt-
mTOR, EGFR and NF-κB (Calay et al., 2010; Freeman et al., 2007; Misra et 
al., 2007; Oh et al., 2007; Patra, 2008; Schley et al., 2007). For example, in 
prostate cancer cells, the change of lipid composition is able to maintain Akt-
regulated cell survival (Oh et al., 2007; Zhuang et al., 2002). Altogether, the 
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lipid rafts may play a paradoxical role in control of cell death and cancer 
development.  
1.4.2. Cav-1 in cancer development 
At present, there is emerging evidence demonstrating the tumor suppression 
function of Cav-1 in several types of cancers, especially in breast cancer 
(Galbiati et al., 2001; Patra, 2008). For instance, expression of oncogenes 
(such as v-Abl and H-ras) leads to a significant decrease of Cav-1 mRNA and 
protein levels (Engelman et al., 1997). Loss of Cav-1 induces the cellular 
transformation through the activation of the p42/44 mitogen activated protein 
kinase (MAPK) cascade and develops an unusual growth pattern with 
increased phospho-ERK1/2 independent of EGF (Galbiati et al., 1998; Sotgia 
et al., 2006). Consistently, over-expression of Cav-1 was sufficient to decrease 
cell proliferation and the tumor size in vivo (Engelman et al., 1997; Koleske et 
al., 1995). On the other hand, Cav-1 has also been reported to have tumor-
promoting effect via promoting tumor metastasis in lung, prostate, breast 
cancers and confined renal cell carcinoma (Campbell et al., 2013; 
Chanvorachote et al., 2014; Ho et al., 2002; Patra, 2008; Patra and Bettuzzi, 
2007; Staubach and Hanisch, 2011; Yamaguchi et al., 2009). Thus, Cav-1 is 
considered to play conflicting and paradoxical roles in cancer development. 
In breast cancer, a large percentage of patients were found to be deficient of 
Cav-1 expression in the cancerous tissues (Sloan et al., 2009). Consistent with 
the clinical findings, several human breast cancer cell lines have also been 
shown to display a decreased Cav-1 expression level compared to benign 
mammary epithelial cells (Bai et al., 2012). Moreover, about 35% breast 
cancer cases contained mutant Cav-1 (Li et al., 2006). For instance, a 
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dominant negative mutant Cav-1 (P132L) has been identified in estrogen 
receptor-positive patients with well-differentiated breast cancer (Lee et al., 
2002; Mercier et al., 2009b). In addition, Cav-1 is reported to be a negative 
regulator for estrogen-induced cell proliferation via regulating the estrogen 
receptor level in mammary epithelial cells (Mercier et al., 2009a; Zhang et al., 
2005). On the other hand, several studies have provided more convincing 
evidence showing that deficiency of Cav-1 expression in the stromal cells in 
breast cancer was closely associated with poor clinical outcomes (Ma et al., 
2013b; Sloan et al., 2009; Witkiewicz et al., 2010; Witkiewicz et al., 2009). 
One possible mechanism for the suppressive function of Cav-1 in tumor 
stromal cell is to regulate the tumor microenvironment (Bonuccelli et al., 2010; 
Pavlides et al., 2010). For instance, loss of Cav-1 in breast cancer-associated-
fibroblasts (CAFs) will increase oxidative stress, leading to the NF-κB 
activation and cytokine production to maintain tumor development 
(Bonuccelli et al., 2010; Martinez-Outschoorn et al., 2010; Pavlides et al., 
2010; Pavlides et al., 2009). However, there is also conflict evidence showing 
an opposite role of Cav-1 in tumor stromal cell. For instance, Cav-1 
expression in breast tumor stroma has shown to increase tumor invasion and 
metastasis via biomechanical remodeling (Goetz et al., 2011). Therefore, the 
exact biological function of Cav-1 in breast cancer and the molecular 
mechanisms remains to be further investigated.  
 
1.5.  SCOPE OF STUDY  
As discussed above, at present the relationship among Cav-1, lipid rafts and 
autophagy has not been clearly elucidated. The molecular mechanisms 
42 
 
underlying the tumor suppressive function of Cav-1 in breast cancer cells have 
not been well defined. Thus, the hypothesis is that the Cav-1 and lipid rafts 
modulate autophagy and via which they play important roles in cell stress 
responses and cancer development. Therefore, to confirm this hypothesis, our 
study will include 3 main parts with the following objectives: 
1. Cav-1 deficiency and lipid rafts disruption enhance autophagy at early 
stage via promotion of autophagosome biogenesis 
a) To confirm whether the disruption of lipid rafts by cholesterol 
depletion or Cav-1 deficiency can enhance autophagy at both basal 
and inducible level. 
b) To study the molecular mechanisms underlying the regulatory role 
of the lipid rafts in early stage of autophagy by focusing on the 
SNARE-mediated autophagosome precursor membrane fusion. 
2. Cav-1 deficiency and lipid rafts disruption enhance autophagy via 
promoting lysosome function at late stage 
a) To confirm whether the disruption of lipid rafts by cholesterol 
depletion or Cav-1 deficiency can promote lysosomal function. 
b) To study the molecular mechanisms underlying the regulatory role 
of the lipid rafts in late stage of autophagy by focusing on the V-
ATPase assembly. 
3. Cav-1 deficiency and lipid rafts disruption-mediated autophagy plays a 
pro-survival role in breast cancer development 
a) To identify the role of lipid rafts and autophagy in stress tolerance in 
breast cancer cells. 
b) To analyze the reduced Cav-1 and lipid rafts level and the enhanced 
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autophagy level in breast cancer cells and cancerous tissues. 
c) To investigate whether the re-expression of Cav-1 in breast cancer 
cells can decrease autophagy activity via recovery of lipid rafts and 
thus lose the resistance to stress conditions 
The present study identifies a novel function of Cav-1 and lipid rafts in 
autophagy regulation. More importantly, understanding the regulatory 
function of Cav-1 and lipid rafts in autophagy not only expands their 
functional scope, but also provides the potential indicator for the suitability of 
using autophagy suppression as a therapeutic strategy for the breast cancer 








2.1. CELL LINES AND CELL CULTURE 
Mouse embryonic fibroblasts (MEFs), MCF7 and L929 cells were grown in 
Dulbecco's Modified Eagle's Medium (DMEM, Sigma, D7777) with 10% FBS 
(Hyclone) and 1% penicillin-streptomycin (Invitrogen) (defined as normal 
medium in this study) in a 5% CO2 incubator at 37°C. The Cav-1 WT and KO 
MEFs were described previously (Razani et al., 2001). MCF-7 cells (1 x 106 
cells) were transfected with 5 μg pEGFP DNA and 5 μg pEGFP-CAV1 DNA 
using Lipofectamine 2000 (Life Technologies, 11668) according to the 
manufacturer's instructions. G418 (Sigma Aldrich) was used as a selection 
drug at 500 μg/ ml for three weeks to establish stable lines. PTRF WT and KO 
MEFs have been previously described (Liu et al., 2008). The Atg5 WT and 
KO MEFs, Atg5 Tet-off inducible MEFs (m5-7) with stable GFP-LC3 
expression and HeLa cells with stable expression of GFP-LC3 were kindly 
gifts from Dr. N Mizushima (Tokyo Medical and Dental University). The 
HeLa cells with stably expressing of HA-VAMP7 was a kindly gift from Dr. 
Peden (University of Cambridge) (Gordon et al., 2009). The TSC2 WT and 
TSC2 KO MEFs were a generous gift from Dr. D. J. Kwiatkowski (Harvard 
Medical School). The tfLC3 stably transfected L929 cells have been reported 
previously (Wu et al., 2009).  
2.2. REAGENTS AND ANTIBODIES 
The chemicals used in this study were: bafilomycin A1 (Baf, Sigma, B1793), 
Methyl-β-cyclodextrin (MBCD, Sigma, C4555), Cholesterol-Water soluble 
(Sigma, C4951), chloroquine diphosphate (CQ, Sigma, C6628), rapamycin 
(Sigma, R8781), Cholera toxin subunit B conjugated with Alexa Fluor 594 
(CTxB, Invitrogen, Cat. C34777), LysoTracker® Green DND-26 (Invitrogen, 
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L7526), LysoTracker® Red DND-99 (Invitrogen, L7528), Magic RedTM 
cathepsin L reagent (Immunochemistry Technologies, LLC, #942), DQTM 
Red BSA (Dye Quenched) (Molecular probes). The antibodies used in this 
study were: LC3 antibody (Sigma, L7543), anti-p62 antibody (Abnova, 
H00008878-2C11), anti-β-actin (Sigma, A5441), p-S6 (S235/236) (CST, 
#2211), anti-transferrin receptor (TfR, Invitrogen, 136800), anti-caveolin-1 
(Cav-1, BD Pharmingen, 610059), anti-TSC2 (Cell signaling, 3990s), mouse 
anti-V-ATPase B2 (Santa Cruz, sc-166122), goat anti-V-ATPase D1 (Santa 
Cruz, sc-69105), anti-PTFR/Cavin-1 (Merck, ABT131). 
2.3. MEASUREMENTS OF LYSOSOMAL FUNCTION 
2.3.1. LysoTracker staining  
The intralysosomal pH was estimated by LysoTracker (Scott et al., 2004; 
Settembre et al., 2011; Zhou et al., 2013). Cells were cultured on coverglass 
slide chamber, then followed with the designated treatments. After 30 min 
incubation with 50nM LysoTracker® Green DND-26 or LysoTracker® Red 
DND-99, the fluorescence intensity of different staining was examined by a 
confocal microscope (Olympus Fluoview FV1000). Representative images 
were selected and photographed. 
2.3.2. Cathepsin activity assay  
The cathepsin L enzymatic activity was detected by Magic RedTM reagent with 
the method described earlier with slight modifications (Ni et al., 2011; Zhou et 
al., 2013). Cells in 24-well plates with indicated treatment were further 
incubated with Magic RedTM cathepsin L reagent for 15 min. The fluorescence 
intensities of 10,000 cells of each sample were quantified by BD FACS 
cytometer (BD Biosciences). 
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2.3.3. Proteolysis activity assay  
Proteolysis activity was performed by DQTM Red BSA staining, conducted 
with the methods reported previously (Ha et al., 2010). MEFs were cultured 
on coverglass slide chamber and preloaded with DQ-BSA (10 μg/ml) for 1hr. 
After three washes with PBS, the medium was changed to the designated 
treatments. Confocal microscopy (Olympus Fluoview FV1000) was used to 
detect the fluorescence intensity. The representative cells were selected and 
photographed. 
2.4. LIPID RAFTS DETECTION 
2.4.1. CTxB staining  
The lipid rafts were stained with CTxB conjugated with Alexa Fluor 594 as 
reported previously with minor modifications (Yamaguchi et al., 2009). 
Briefly, MEFs were seeded on coverglass slide chamber. After the incubation 
and indicated treatments, cells were loaded with 1 μg/mL CTxB for 15 min on 
ice and then washed with PBS and followed a 30 min incubation at 37°C. The 
fluorescence intensities was observed under a confocal microscope (Olympus 
Fluoview FV1000). Representative fields were selected and photographed. 
2.4.2. Filipin staining  
For cholesterol staining, the cells were labelled by Filipin III (Sigma, F4767) 
as reported previously (Hill et al., 2008; Inder et al., 2012). Briefly, cells were 
seeded and treated on coverglass slide chamber. After treatments, cells were 
fixed by 4% paraformaldehyde for 30 min and quenched in 50 mM NH4Cl3 for 
10 min. Then cells were blocked, permeabilized and stained in the solution 
which containing 0.2% BSA, 0.2% fish skin gelatin with 50 μm of Filipin III 
for 20 min. After three time washes in PBS, the fluorescence intensity was 
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examined under a confocal microscope (Olympus Fluoview FV1000). 
Representative images were photographed. 
2.5. CELL FRACTIONATION 
2.5.1. Lipid rafts fractionation  
Isolation of detergent-resistant lipid rafts fraction (DRF) from detergent-
soluble fraction (DSF) was performed based on previously study with minor 
modifications (Lingwood and Simons, 2007; Sonnino and Prinetti, 2013; Tan 
et al., 2014). The principles of this method are shown as Fig 2.1. Briefly, after 
indicated treatments, cells were washed by ice-cold PBS and collected to 
centrifuge at 2000 r.p.m. 4°C for 3 min. Then cells were homogenized with 
TNE buffer (25mM Tris HCl, pH 7.4, 150mM NaCl, 3mM EDTA and Roche 
protease inhibitor cocktail) supplied with 1% Triton-100 by passage through a 
27-gauge needle for 20 times on ice. The collected cell then lysed on ice for 30 
mins. Afterward, spin down the samples at 16,000 g at 4°C for 20 min, and the 
supernatants were collected as the DSF. The insoluble pellets were 
resuspended and lysed in the Laemmli SDS buffer as described in Western 




Figure 2.1 Lipid rafts fractionation (Modified from (Sonnino and Prinetti, 
2013)) 
 
2.5.2. Lysosome fractionation  
The isolation of lysosome was performed according the manufacturer’s 
protocol of the Lysosome Enrichment Kit for Tissue and Cultured Cells 
(Thermo Scientific, 89839). Cells cultured in 3 × 150mm2 culture dishes with 
indicated treatments were subjected to be isolated. Each fraction was 
examined by western blotting. 
2.6. PROXIMITY LIGATION ASSAY (PLA) 
Cells were cultured in coverglass slide chamber and treated as indicated. Then 
after fixation by 4% paraformaldehyde and permeabilization by 0.1% saponin, 
the cells were subjected to PLA by Duolink detection kit (Olink Bioscience) 
(Kim et al., 2012). Briefly, permeabilized cells were blocked and incubated 
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with mouse anti-V-ATPase B2 and goat anti-V-ATPase D1 antibodies 
overnight at 4°C. Then after incubation with secondary antibodies conjugated 
to unique DNA probes (anti-mouse and anti-goat for two primary antibodies, 
provided by the kit), a rolling circle amplification step were used to subject to 
the proximity ligation (<40 nm) and circularization of the DNA. After the 
amplification process, replication of the DNA circle were labelled by 
complementary oligonucleotide probes and the signal were examined under 
confocal microscope (Olympus Fluoview FV1000). Representative fields were 
selected to present. 
2.7. CAV-1 IMMUNOHISTOCHEMISTRY 
The paraffin-embedded tissue sections of 7 breast cancer and their adjacent 
normal tissue samples were collected from Tissue Repository (NUHS) with 
the approval from NUS IRB. To determine the Cav-1 expression level, 
sections are dewaxed and rehydrated using standard dewaxing protocol. Then 
the samples were subjected to heat antigen retrieval by 10 mM Citric acid 
buffer (pH 6.0 for 15 min at 105 ℃). Endogenous peroxidase activity is 
blocked by a 10 min incubation with 3% H2O2. Then the samples were 
blocked by 3% BSA and incubated with the 1:100 dilution of the anti-Cav-1 
primary antibody overnight at room temperature (RT) in a humid chamber. 
Envision HRP anti rabbit polymer is added for 30 min at RT. Colour is 
developed by incubation with DAB for 5 min, followed a counterstain with 
Mayers’ haematoxylin. Then the sections were dehydrated through ascending 
graded alcohols, cleared in xylene, mounted and visualized. Representative 
cells were selected and photographed. To quantify the immunohistochemistry 
result of positive staining intensity, three observations of each samples were 
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analyzed by an experienced pathologist. Motic Images Advanced software 
(version 3.2, Motic China Group) was used to analyze the protein level. Data 
were presented as Means ± SD were presented and analysed using the 
Student’s t test. 
2.8. DETECTION OF CELL DEATH 
Several methods were used to detect cell death quantitatively and qualitatively, 
which are (i) morphological changes under phase-contrast microscopy, (ii) 
propidium iodide (PI) exclusion assay coupled with flow cytometry (5 µg/ml). 
For PI exclusion assay, trypsinized cells with the medium in each well were 
collected. The pellets were resuspended into phosphate buffer saline (PBS) 
containing 5 μg/ml PI. Then 10,000 cells from each sample were analyzed by 
BD FACS cytometer (BD Biosciences). 
2.9. TRANSIENT SIRNA TRANSFECTION 
According to the manufacturer’s protocol, 100 nM of either the non-specific 
control, mouse VAMP7 siRNA (ON-TARGET plus SMARTpoolTM) were 
transfected by using DharmaFECTTM 4 siRNA Transfection reagent 
(Dharmacon) to Cav-1 WT and Cav-1 KO MEFs cultured in 6-well plate. 
Then after 48 hours transfection, cells were re-seeded and incubated overnight 
for the designated treatments. 
2.10. DNA EXTRACTION 
According to the volume of DNA required in the study, Qiagen Miniprep 
Plasmid Extraction Kit and Qiagen Maxiprep Plasmid Extraction Kits were 
used for DNA extraction. The miniprep kit was used for the smaller amount of 
DNA extractions, while the Maxiprep kit was used for larger amount of DNA 
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extractions. Briefly, according to the manufacturer's protocol, bacterial with 
plasmid transduction was first centrifuged to obtain the cell pellet (supernatant 
was discarded). Then the cell pellets were suspended in a series of buffers and 
collected by the columns provided by the extraction kits. The quality and 
concentration of DNA was analyzed by NanoDrop 1000 Spectrophotometer 
(Thermo Scientific). 
2.11. RNA EXTRACTION 
RNeasy Mini kit (Qiagen) were utilized for RNA extraction from cultured cell 
according to the manufacturer's protocol. NanpDrop 1000 Spectrophotometer 
(Thermo Scientific) were used to analyze the concentration and quality of 
extracted RNAs. 
2.12. REVERSE TRANSCRIPTASE AND QUANTITATIVE REAL-TIME 
POLYMERASE CHAIN REACTION 
High Capacity cDNA Reverse Transcription kit (Applied Biosystems) was 
utilized for reverse transcription reaction according to the manufacturer's 
protocol. The Cav-1 primer set (Cav-1: forward, CGTAGACTCGG-
AGGGACATC and reverse, ACTTGCTTCTCGCTCAGCTC) were used for 
Quantitative RT-PCR. SsoFast EvaGreen (Bio-Rad, #1725201AP) were used 
in a thermal cycler (model C1000TM, Bio-rad). All samples were normalized 
to GAPDH (glyceraldehydes-3-phosphate dehydrogenase) expression levels. 
2.13. PLASMIDS AND TRANSIENT TRANSFECTION 
The mRFP-GFP tandem fluorescence-tagged LC3 construct (tfLC3) and 
Stawberry-Atg16L was a kindly gift provided by Dr. T. Yoshimori (Osaka 
University) (Kimura et al., 2007). VAMP7-mRFP vector was kindly provided 
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by Dr. Galli (University Denis Diderot) (Burgo et al., 2009). For transient 
transfection, Lipofectamine 2000 transfection reagent (Invitrogen) was used 
according to the manufacturer’s protocol. Briefly, the cells were transfected 
with the plasmids for 24 hours and re-seeded before being subjected to the 
designated treatments.  
2.14. WESTERN BLOTTING 
After the designated treatments, Laemmli SDS buffer were used to lyse the 
collected samples (62.5 mM Tris pH 6.8, 25% glycerol, 2% SDS, phosphatase 
inhibitor and proteinase inhibitor cocktail). Each samples was resolved by 
SDS-PAGE with equal amount, then the SDS-PAGE gel were transferred onto 
PVDF membrane (Bio-Rad, 162-0177). Membranes were blocked for 30 min 
with blocking buffer (Thermo, 37538) and followed the incubations with 
indicated primary and secondary antibodies. Then the membrane was 
visualized with the enhanced chemiluminescence method (Thermo Scientific, 
#34076) by the ImageQuant LAS 500 (GE). 
2.15. IMMUNOPRECIPITATION 
The immunoprecipitation (IP) assay was performed based on previously 
reports with minor modifications (Ikenoue et al., 2009). Briefly the cells were 
lysed on ice for 30 minutes with the IP buffer (40 mM HEPES, pH 7.4, 120 
mM NaCl, 2 mM EDTA, 0.3% CHAPS, 10 mM pyrophosphate, 10 mM 
glycerophosphate, 50 mM NaF, phosphatase and protease inhibitor mixture). 
Cell lysates which containing 1 μg protein of each treatment were incubated 
with the same amount of antibody and mixed overnight with gentle rocking at 
4°C. Then, after addition of 30 μl of Sepharose protein A/G-agarose beads, the 
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cell lysates were mixed for 1 hour at 4°C under gentle rocking to form 
immunoprecipitates. Immunoprecipitates were washed 3 times in IP Buffer 
and the immunoprecipitated complexes were eluted by boiling for 5 minutes in 
sample buffer (Bio-Rad). Lastly, the eluted immunoprecipitated complexes 
were resolved on SDS-PAGE gel and transferred onto PVDF membrane (Bio-
Rad) for immunoblotting analysis. 
2.16. IMAGE ANALYSIS 
For quantification of mRFP+ and GFP+ structures (mRFP-GFP tandem 
fluorescent‑tagged LC3), the Analyze Particle plugin in ImageJ (NIH) was 
used for analysis. Within the same experiment, a constant threshold was 
applied for all images. Colocalization analysis between two channels was 
performed using the colocalization plugin in ImageJ (NIH). For the velocity 
calculation of the live image of the Stawberry-Atg16L vesicles, Manual 
tracking plugin in ImageJ (NIH) was used. Quantification was carried out on 
at least 20 cells per condition from independent experiments. 
2.17. ANALYSIS OF AUTOPHAGIC FLUX BY LC3-II LEVELS USING LYSOSOME 
INHIBITORS 
Autophagic flux is the complete flow of autophagosomes from the initiation to 
fusion with lysosomes for degradation. A reliable marker of autophagosomes 
is LC3, a mammalian homolog of yeast Atg8. Both of the autophagosome 
formation and degradation affect the levels of LC3-II. Thus, autophagic flux is 
detected by blocking LC3-II/autophagosome degradation with lysosome 
inhibitors, CQ and Baf. CQ/Baf will inhibit LC3-II degradation by blocking 
lysosomal function and autophagosomes–lysosome fusion, resulting in 
increased LC3-II levels compared to the basal (untreated) state (Mizushima et 
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al., 2010). This is a well–established method for monitoring autophagosome 
synthesis (Klionsky et al., 2012). The LC3-II changes under different 
autophagy status were shown in Figure 2.2 (Ref). In our study, autophagy flux 
was examined by measuring LC3-II levels in the presence of 50 nM Baf or 
20μM CQ for the indicated time. Then the cells were harvested for 
immunobloting analysis with anti-LC3 antibody, as established in our earlier 
study (Klionsky et al., 2012; Zhou et al., 2013). 
 
Figure 2.2 Analysis for autophagic flux in different conditions by using 
lysosome inhibitors (Modified from (Mizushima et al., 2010) ) 
 
2.18. ANALYSIS OF AUTOPHAGOSOME-LYSOSOME FUSION WITH MRFP-
GFP-LC3 REPORTER 
The analysis of autophagosome-lysosome fusion were performed by the using 
a pH–sensitive, tandem–fluorescent–tagged mRFP-GFP-LC3 reporter (Kimura 
et al., 2007). Autophagosomes are labeled with both mRFP and GFP signals, 
while the autolysosomes quench the acid-lablile GFP signal because of their 
acidic lysosomal environment (Figure 2.2). L929 cells with stable transfection 
of mRFP-GFP-LC3 construct were used for indicated treatments, then 
observed under confocal microscope. Quantification of mRFP and GFP 




Figure 2.3 mRFP-GFP-LC3 color change (Sarkar et al., 2013) 
 
2.19. STATISTICAL ANALYSES 
All image and western blot data presented above are representatives from 
three independent experiments. The numeric data are presented as means ± SD 
from at least 3 independent experiments and analyzed by the Student t test, 
one way ANOVA or two way ANOVA (depend on different situation) . The p 
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Lipid rafts are liquid-ordered micro-domains composed by a characteristic 
structural composition (sphingolipids, cholesterol and saturated phospholipids) 
in plasma membrane and intracellular membranes system, including Golgi, ER, 
mitochondria and endosome/lysosome (Lingwood and Simons, 2010; Sonnino 
and Prinetti, 2013; Waheed and Freed, 2010). There are mainly two types of 
lipid rafts proposed, the planar lipid rafts (also known as non-caveolar rafts) 
and caveolae (flask-shaped structures) (Allen et al., 2007). In recent years, 
lipid rafts have been reported to play crucial role in various cellular processes, 
including cellular signaling transduction, cytoskeletal organization, membrane 
trafficking in the whole membrane system (George and Wu, 2012; Levental et 
al., 2010; Lingwood et al., 2009; Staubach and Hanisch, 2011). Caveolae, 
estimated to be 25-100 nm in diameter, appear to act as platforms that function 
in intracellular signaling and trafficking by facilitating protein–protein 
interactions via Cav-1, the principal scaffolding protein of caveolae (Levental 
et al., 2010; Sotgia et al., 2012). In addition, Cav-1 is reported to play an 
important role in the cholesterol trafficking and homeostasis (Bosch et al., 
2011; Le Lay et al., 2009). Since cholesterol is critical for both types of lipid 
rafts, the involvement of Cav-1 in cholesterol homeostasis may indicate its 
function in general lipid rafts regulation  (Mundy et al., 2012; Robenek et al., 
2004; Schlegel et al., 2001). 
Autophagy is an evolutionarily well-conserved “self-eating” process in 
eukaryotic cells that results in degradation of long-lived proteins and 
organelles via the lysosomal pathway, which serves as a powerful booster of 
metabolic homeostasis (Choi et al., 2013; Rubinsztein et al., 2012). The whole 
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autophagy process is controlled by a group of proteins encoded by autophagy-
related-genes (Atgs) in several consecutive stages. The initiation of autophagy 
starts with emergence of phagophore or preautophagosomal structure, and is 
regulated by the ULK1/Atg1 complex downstream of mammalian target of 
rapamycin complex 1 (mTORC1) (Calay et al., 2010; Grider et al., 2009). The 
initiation step is then followed by the nucleation/expansion/elongation process. 
This process is mediated by Class III PI3K-Beclin-1 complex (Backer, 2008). 
Moreover, the completion of autophagosome formation is controlled by two 
conjugation systems: Atg12-Atg5-Atg16 and LC3-PE. Recent studies have 
found that the elongation process requires membrane hemifusion driven by 
SNAREs (Itakura et al., 2012; Mizushima et al., 2011; Moreau et al., 2011; 
Nair et al., 2011; Takats et al., 2013). The final step of autophagy is the 
maturation and degradation, in which the outer membrane of the 
autophagosome fuses with a lysosome to form an autolysosome where the 
inner membrane and luminal contents are degraded via acidic lysosomal 
hydrolases (Choi et al., 2013). One key feature of autophagy is that it involves 
various intracellular membrane structures, including autophagosomes, 
lysosomes and autolysosomes. At present, several studies have implicated 
Cav-1 and lipid rafts in the regulation of autophagy. For instance, Cav-1 
deficiency is able to induce autophagy in adipocytes via suppression of insulin 
and lipolytic responses (Le Lay et al., 2010). Loss of Cav-1 is able to promote 
autophagy under hypoxia and oxidative stress in adipocytes and fibroblasts 
(Martinez-Outschoorn et al., 2011). These studies indicate a suppressive role 
for Cav-1 in autophagy. Furthermore, there are several clues indicating the 
potential roles of lipid rafts in autophagy. For instance, lipid rafts are reported 
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to promote the Akt-mTOR pathway (Calay et al., 2010; Grider et al., 2009), a 
key negative regulator of autophagy (Calay et al., 2010; Grider et al., 2009). In 
contrast, there are conflicting evidence indicating that some components of 
lipid rafts, such as ceramides and GD3 ganglioside, play a positive in 
autophagy (Matarrese et al., 2014; Peralta and Edinger, 2009; Scarlatti et al., 
2004). 
SNAREs are a superfamily of membrane-associated proteins, which is 
essential to mediate membrane fusion events (Lang, 2007). They have a 
characteristic evolutionarily conserved stretch of 60-70 amino acid, which is 
called SNARE motif (Jahn and Scheller, 2006). SNAREs are known to play 
important role in autophagy regulation. Recent studies found that the 
elongation process required membrane hemifusion driven by SNAREs (Fraldi 
et al., 2010; Itakura et al., 2012; Mizushima et al., 2011; Moreau et al., 2011; 
Nair et al., 2011; Takats et al., 2013). For example, VAMP7, which is a 
member of SNAREs family, is reported to promote Atg12-Atg5-Atg16L 
complex formation, which induce the following autophagy (Moreau et al., 
2011). In addition, SNAREs are reported to concentrate in lipid rafts 
microdomains, indicating a regulatory role of lipid rafts in SNAREs 
(Chamberlain et al., 2001; Lang, 2007; Xia et al., 2004). The lipid rafts is 
proved to play important roles in balancing the mono- and complex- forms of 
SNAREs to maintain the cycle for new fusion events (Fraldi et al., 2010; Lang, 
2007). However, there is no direct evidence to link lipid rafts to autophagy via 
SNAREs. 
In this part of our study, we demonstrate an increased autophagy flux after 
lipid rafts disruption by Cav-1 deficiency and cholesterol depletion. And the 
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enhanced autophagosome formation is mediated by lipid rafts disruption via 
promoting VAMP7 activity on mediating Atg16L hymofusion. 
3.2. RESULTS 
3.2.1. Cav-1 deficiency and lipid rafts disruption induces autophagy flux 
3.2.1.1. Cav-1 deficiency decreases lipid rafts level and enhances autophagy 
The effect of Cav-1 deficiency on autophagy was tested by using Cav-1 WT 
and KO MEFs (Razani et al., 2001). Absence of the Cav-1 protein was 
confirmed in Western blots (Figure 3.1A). To confirm whether the Cav-1 KO 
cells have a lower level of lipid rafts, the lipid rafts level using Alexa Fluor 
594–conjugated CTxB staining was assessed in both Cav-1 WT and KO cell 
lines (Yamaguchi et al., 2009). As shown in Figure 3.1B, Cav-1 KO cells 
showed markedly reduced CTxB signal in comparison to the WT MEFs, 
indicating a lower level of lipid rafts in Cav-1 KO cells. These results were 
confirmed by labeling the cholesterol directly using filipin (Figure 3.1C). Cav-
1 KO cells also have a lower level of filipin signal when observed under 
confocal microscope. Next, this cell model was utilized to compare the 
autophagy levels by evaluating the well-established autophagy marker LC3-II 
in normal and amino acid starvation conditions. It was found that under both 
conditions, LC3-II level was higher in Cav-1 KO cells (Figure 3.1D). 
Moreover, to measure the autophagic flux, the autophagosomal degradation 
was inhibited by lysosomal inhibitor CQ, and observed a further increase in 
LC3-II protein levels in Cav-1 KO cells (Figure 3.1D), excluding the 
possibility that the increased LC3-II was caused a blockage of 
autophagosomal degradation. These data suggest that Cav-1 deficiency 




Figure 3.1 Cav-1 deficiency and lipid rafts disruption induces autophagy 
flux. (A) Cav WT and KO cell identity was shown by western blots. (B) Lipid 
rafts marker CTxB (Red) staining in Cav-1 WT and KO MEFs. (C) 
Cholesterol indicator Filipin (blue) staining of both Cav-1 WT and KO MEFs. 
Scale bar, 10 µm. (D) Autophagic flux was detected by the treatments with or 






3.2.1.2. Disruption of lipid rafts by cholesterol depletion induces autophagy 
To further understand the role of lipid rafts in autophagy, the lipid rafts 
disruption agent MBCD, which depletes cholesterol from the membranes, was 
used (Kilsdonk et al., 1995). Since the cholesterol is the main component of 
lipid rafts (Allen et al., 2007), depletion of cholesterol should disrupt the lipid 
rafts. The disruptive effects of MBCD treatment were confirmed by using 
three different observations: (i) reduction of Alexa Fluor 594–CTxB staining, 
(ii) filipin staining and (iii) loss of Cav-1 in the isolated rafts fraction and the 
accumulation in non-rafts fraction (Lingwood and Simons, 2007; Sonnino and 
Prinetti, 2013; Tan et al., 2014). Firstly, the filipin staining data indicatd that1 
h MBCD exposure was enough to deplete the membrane cholesterol level 
(Figure 3.2A). Then the observation of decreased CTxB staining after MBCD 
treatment confirmed a disrupted level of lipid rafts (Figure 3.2B). To further 
confirm this result, we isolated the lipid rafts fraction and the non-lipid rafts 
fraction by detergent-resistant fractionation. The redistribution of lipid rafts 
proteins from lipid rafts fraction to non-rafts fraction is a marker for the 
disruption of lipid rafts (Lingwood and Simons, 2007; Sonnino and Prinetti, 
2013; Tan et al., 2014). As expected, the MBCD exposure indeed caused the 
lipid rafts protein Cav-1 redistributing from detergent-resistant lipid rafts 
fraction (DRF, representing the lipid rafts components) to detergent-soluble 
fraction (DSF, representing the non-lipid rafts components, using transferrin 
receptor (TfR) as the marker) in both time and dose dependent manner (Figure 
3.2C & 3.2D), indicating that MBCD is able to disrupt lipid rafts effectively. 
Thus, 5 mM MBCD for 1 h pre-treatment and following by 2-6 h designed 
treatments was utilized in the following experiments. 
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In next step, the effect of lipid rafts disruption by MBCD on autophagic flux 
was assessed by the same methods as described previously. The MEFs with 
GFP-LC3 stable expression were then used to detect the autophagic flux. As 
expected, in both basal and amino acid starvation conditions, MBCD pre-
treatment for 1 h further increased the GFP-LC3 puncta with the presence of 
CQ (Figure 3.3A), suggesting an increased autophagix flux in both conditions. 
Then this result was confirmed by the further increased LC3-II level (Figure 
3.3B) in normal as well as amino acid starvation and rapamycin with the 
presence of CQ, indicating an increased autophagic flux. These observations 
demonstrate that disruption of lipid rafts by cholesterol depletion (MBCD 
treatment) increases both basal and inducible autophagy level. In addition, a 
similar effect of MBCD on autophagy was observed in HepG2 cell line 
(Figure 3.4), which confirmed this effect is not cell line specific.  
To exclude the possibility that MBCD-mediated autophagic flux observed 
above was caused by the non-specific effects of MBCD, we used cholesterol 
(CHO) replenishment to restore the lipid rafts and checked whether this 
restoration would rescue the disruption effect. As shown in Figure 3.5A and 
3.5B, CHO replenishment indeed recovered the decreased intensity of CTxB 
staining and the redistribution of Cav-1 from rafts fraction to non-rafts fraction 
caused by MBCD, which are all comparable to control cells. This evidence 
thus indicates the effective recovery of CHO replenishment to the MBCD 
depletion. As expected, the CHO replenishment inhibited the autophagic flux 
induced by MBCD, based on the observations of markedly reduced LC3-II 
level in the presence of CQ (Figure 3.5C).  
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The above observations suggest that both Cav-1 deficiency and cholesterol 
depletion by MBCD treatment induce autophagy via disruption of lipid rafts. 
Next, MBCD treatment was performed in Cav-1 KO cells. As shown in Figure 
3.6, comparing to Cav-1 WT cells, MBCD treatment was shown to be less 
effective in inducing autophagy in Cav-1 KO cells, suggesting the impaired 
function of lipid rafts in the cells deficient of Cav-1. These data further 
confirmed that the disrupted lipid rafts, instead of Cav-1 or cholesterol, is 





Figure 3.2 Cholesterol depletion by MBCD disrupts lipid rafts. (A) 
Cholesterol indicator Filipin (blue) staining after MBCD treatment (5 mM, 1 
h). Scale bar, 10 µm. (B) Lipid rafts marker CTxB (Red) staining after same 
treatment described in panel (A). (C) Cells were treated with MBCD in 
indicated dose, then after lipid rafts fractionation, both lipid rafts fraction 
(DSF) and non-rafts fraction (DRF) were immunoblotted with indicated 
markers. (D) After 1 h MBCD pre-treatment (5mM) and following the normal 
medium incubation as indicated time, cells were fractioned into DSF and DRF. 




Figure 3.3 Disruption of lipid rafts by cholesterol depletion induces 
autophagy. (A) MEFs with stably expressing of GFP-LC3 were pre-treated 
with or without MBCD (5 mM) for 1 h, then incubated in both normal DMEM 
and amino acid free medium (AA-) with or without CQ (20 µM) for 2 h. The 
GFP-LC3 punctuation were observed under a confocal microscope (×600). 
Scale bar, 10 µm. The mean florescence intensity were analyzed by ImageJ, 
means±SD were presented. (B) Cells were pretreated with or without MBCD 
(5 mM) for 1 h, then treated by normal DMEM, amino acid free medium (AA-) 
and Rapamycin (Rapa, 20 µM) with or without CQ (20 µM) for 2 h, and cell 






Figure 3.4 Lipid rafts disruption induces autophagy in HepG2 cells. (A) 
HepG2 cells were pre-treated with MBCD (10 mM, 1 h) and then treated with 
or without CQ (20µM) or Baf (Bafilomycin A1, 50nM) for 5 h. After lipid 





Figure 3.5 Cholesterol (CHO) replenishment restores lipid rafts and 
overcomes the effect of MBCD on autophagy (A) MEFs were pretreated 
with or without MBCD (5 mM) for 1 h, then incubated in the presence or 
absence of CHO (30 µg/ml) and CQ (20 µM). The cells were stained with 
CTxB (Red) and observed under confocal microscope. Scale bar, 10 µm. (B) 
Cells were treated as in panel (A), then fractioned into DSF and DRF. Both 
lysates were separated and immunoblotted with indicated markers. (C) Cells 
were treated as in panel (A), with or without CQ (20 µM). The total cell 
lysates were then immunoblotted with indicated markers. 
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Figure 3.6 MBCD disruption does not further enhance autophagy flux in 
Cav-1 KO MEFs. Cav-1 WT and KO MEFs were pretreated with or without 
MBCD (5 mM) for 1 h, then incubated in the presence or absence of CQ (20 






3.2.1.3. Lipid rafts disruption-mediated autophagy is independent of PTRF-
related caveolae 
In this part of our study, the involvement of caveolae in elevated autophagy 
was further studied. PTRF is known to be required for caveolae formation 
(Inder et al., 2012; Nassar et al., 2013). Deficiency of PTRF blocks caveolae 
formation and promotes Cav-1 degradation (Hill et al., 2008; Hill et al., 2012). 
Consistently with previous findings, we found a lower Cav-1 level in PTRF 
KO cells, and CQ increased Cav-1 level via blockage of lysosomal 
degradation (Figure 3.7A). Then, the difference of lipid rafts level between the 
PTRF WT & KO cells was compared. Interestingly, we found both CTxB and 
filipin staining did not differ between PTRF-WT and KO MEFs (Figure 3.7B 
& 3.7C). The autophagy level was also comparable in these two cell lines 
under basal and amino acid starvation conditions (Figure 3.7A). Moreover, 
disruption of lipid rafts by MBCD had a similar effect on both PTRF-WT and 
KO cells (Figure 3.7A). Taken together, these data indicate a possibility that 
the Cav-1 containing planar lipid rafts, but not PTRF-related caveolae, play an 




Figure 3.7 PTRF has no effect on lipid rafts and autophagy. (A). PTRF-
WT and KO MEFs were pretreated with or without MBCD (5 mM) for 1 h, 
then incubated in both normal DMEM and amino acid free medium (AA-) 
with or without CQ (20 µM) for 2 h, then cell lysates were subjected to 
Western blot analysis for the indicated markers. (B-C). PTRF-WT and KO 
MEFs were pretreated with or without MBCD (5 mM) for 1 h. Then PTRF-
WT and KO MEFs were stained with CTxB (B) and Filipin (C). Cells were 
observed under a confocal microscope (×600). Scale bar, 10 µm. 
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3.2.2. Cav-1 deficiency and lipid rafts disruption promote 
autophagosome formation via engaging VAMP7  
3.2.2.1. Lipid rafts disruption-induced autophagy is independent of mTOR 
activity 
Lipid rafts are known to be implicated in the AKT-mTOR signalling pathway, 
which is a key negative regulator of autophagy (Calay et al., 2010; Grider et 
al., 2009). Next the involvement of mTORC1 in autophagy induced by lipid 
rafts disruption was tested. As shown in Figure 3.8A, MBCD disruption did 
not show a significant inhibitory effect on phosphorylation of mTOR (S2448) 
and mTOR downstream target protein S6 (Ser235/Ser236). Consistently, no 
difference was found in the phosphorylation level of S6 between Cav-1 WT 
and KO MEFs (Figure 3.8B). These data might indicate that the inhibitory 
effects of lipid rafts on autophagy bypass mTOR pathway in our model. 
To confirm this result, the TSC2 WT and KO MEFs were utilized. TSC2 is an 
essential component to form a functional heterodimer to suppress mTORC1 
activity, and loss of TSC2 leads to the constitutive mTOR activation and 
impaired autophagy (Inoki et al., 2002; Ng et al., 2011; Zoncu et al., 2011). 
The effects of MBCD disruption between TSC2-WT (normal activation of 
mTORC1) and TSC2 KO cells (constitutive activation of mTORC1) were then 
compared. The effects of MBCD disruption on the autophagic flux were found 
to be similar between TSC WT and TSC2 KO MEFs (Figure 3.8A), which 
suggest that mTORC1 is unlikely to play a role in autophagy-mediated by 





Figure 3.8 Disruption of lipid rafts does not affect mTORC1 activity. (A) 
TSC2 WT and KO MEFs were pre-treated with or without MBCD (5 mM) for 
1 h, then incubated in the presence or absence of CQ (20 µM). Cell lysates 
were collected and subjected to western blots for the indicated markers. (B) 
Similar mTOR activity level between Cav-1 WT and KO MEFs. Cell lysates 







3.2.2.2. Lipid rafts disruption accelerates Atg16L protein mobility and 
promotes fusion capability 
In this part of our study, the effect of lipid rafts on autophagosome biogenesis 
was examined. 
First, the changes of Atg16L-positive vesicles was detected. The homotypic 
fusion of Atg16L containing autophagic precursors is reported to be required 
for Atg5-Atg12 conjugation (Moreau et al., 2011). As shown in Figure 3.9A & 
B, after transfection of Stawberry-Atg16L, the MBCD disruption significantly 
increased the size of Atg16L positive vesicles. the effect of amino acid 
starvation was also detected, which is a classical autophagy inducer, on 
Atg16L positive vesicles as a positive control. Interestingly, the increase of 
Atg16L positive vesicles size was comparable between amino acid starvation 
and MBCD treatment, indicating that MBCD disruption might trigger the 
fusion of Atg 16L vesicles which follow the same scenario in amino acid 
starvation-induced autophagy. 
Second, the live image data of the Atg16L positive vesicles movement was 
analyzed by measuring the vesicle velocity. MBCD increased the velocity of 
Atg16L-positive vesicles, similar to amino acid starvation used as the positive 
control. Thus our data indicate that lipid rafts disruption accelerates Atg16L 
containing vesicles mobility and promotes fusion capability, providing a 





Figure 3.9 Lipid rafts disruption accelerates Atg16L protein mobility. (A). 
HeLa cells with transit transfection of Strawberry-Atg16L were pre-treated 
with MBCD (5mM) for 1h, or treated with amino acid free starvation for 2h. 
Then cells were observed by confocal microscope (X600) for 10 min by 
scanning every 30s. Scale bar, 10 µm. (B) The average size of Atg16L 
vesicles in panel (A) are presented as means±SD and analyzed by statistical 
analysis. Statistical significance for pairwise comparisons evaluated with a 
two-tailed Student’s t-test. (C) The velocity of Atg16Lvesicles was analyzed 
by ImageJ and presented as means ±SD, followed by statistical analysis (same 
as in Panel B).   
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3.2.2.3. Lipid rafts disruption enhances the Atg16L-LC3 puncta co-
localization 
Since the homotypic fusion of autophagic precursor containing Atg16L leads 
to LC3 acquisition during autophagosome formation process (Moreau et al., 
2011), we then examined whether the increased fusion of Atg16L positive 
vesicles after lipid rafts disruption would lead to the fusion of Atg16L and 
LC3 positive puncta.  
In HeLa cells with stable expression of GFP-LC3 and transit expression of 
Strawberry-Atg16L1, after both amino acid starvation and MBCD disruption, 
as expected, the co-localization between Stawberry-Atg16L and GFP-LC3 
puncta after both amino acid starvation and MBCD treatment was significantly 
increased (Figure 3.10), indicating that the Atg16L-positive vesicles after lipid 







Figure 3.10 Lipid rafts disruption enhances Atg16L-LC3 fusion. HeLa 
cells with stable expression of GFP-LC3 and transit transfection of 
Strawberry-Atg16L1 were pre-treated with MBCD (5 mM) for 1 h, or treated 
with amino acid free starvation for 2 h. Then cells were observed by confocal 






3.2.2.4. Lipid rafts disruption promotes VAMP7-induced homotypic fusion of 
Atg16L 
The VAMP7-containing SNAREs complex is known to interact with Atg16L 
from the plasma membrane undergo homotypic fusion (Moreau et al., 2011). 
Thus, to explore the role of SNARE protein VAMP7 in MBCD-induced 
autophagosome formation, the VAMP7 function after MBCD treatment was 
detected by observing the interaction between VAMP7 and Atg proteins. In 
GFP-LC3 stable expressed HeLa cells, we transfected the RFP-VAMP7 
construct. The co-localization between RFP-VAMP7 and GFP-LC3 signal 
were increased after MBCD pre-treatment, especially in amino acid starvation 
conditions (Figure 3.11A). Second, to confirm the interaction between 
VAMP7 and Atg proteins, the HeLa cells with stable expression of HA-
VAMP7 were utilized. After MBCD treatment, the HA antibody was used to 
pull-down the HA-VAMP7 complex. And a significant increase of Atg5 and 
LC3 accumulation was detected in VAMP7 complex after MBCD treatment 
(Figure 3.11B), demonstrating an increased interaction between VAMP7 and 
the Atg proteins in cells with disrupted lipid rafts. Interestingly, as shown in 
Figure 3.12, a decrease of interaction between VAMP7 and Cav-1 was 
observed, which indicates that the release of VAMP7 from Cav-1 binding or 
lipid rafts domain promotes the interaction between VAMP7 and Atg proteins. 
Since there are reports suggesting a inhibitory function of lipid rafts or Cav-1 
on SNAREs function (Fraldi et al., 2010; Salaun et al., 2005), the evidence we 
provided here indicates that the interaction between VAMP7 and Cav-1 




Figure 3.11 Lipid rafts disruption promotes the interaction between 
VAMP7 and Atg proteins. (A) HeLa cells with stable expression of GFP-
LC3 and transit transfection of RFP-VAMP7 were pre-treated with MBCD (5 
mM) for 1 h, or treated with normal or amino acid free medium (AA-) for 2 h. 
Then cells were observed by confocal microscope (X600, 6-7 sections for one 
field, 0.1 μm/section). The three small figures in the right side of every panel 
are 3 difference sections of the indicated field (labelled by white box). Scale 
bar, 10 µm. The Pearson Rr of the image data from panel (A) was analyzed by 
the ImageJ colocalization finder plugin. (B) HeLa cells with stable expression 
of HA-VAMP7 were treated with MBCD (5 mM) for 1 h. Co-IP was 
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performed by HA antibody, then immunoblotted with indicated markers with 
different exposure times (short exposure (SE) & long exposure (LE)) 
 
Figure 3.12 Lipid rafts disruption decreases the colocalizaition between 
Cav-1 and VAMP7. HeLa cells with transit transfection of RFP-VAMP7 
were treated with MBCD pre-treatment (5 mM, 1 h) and followed by normal 
or amino acid starvation incubation. Then the cells were immunostained by 






3.3.1. Autophagy induction by lipid rafts disruption 
It has been reported that autophagy is able to regulate lipid metabolism 
through lipophagy (Rabinowitz and White, 2010; Rubinsztein et al., 2012), 
while it is still controversial whether lipid rafts, which is a lipid microdomain 
with specific components, is able to regulate autophagy. The data in this study 
indicates that lipid rafts disruption by either pharmacological or genetic 
approaches promotes both basal and inducible autophagy, indicating a 
suppressive role of lipid rafts per se in autophagy regulation. Our findings are 
generally consistent with early reports that both Cav-1 and lipid rafts can be 
considered as a negative regulator of autophagy (Fraldi et al., 2010; Grider et 
al., 2009; Le Lay et al., 2010; Martinez-Outschoorn et al., 2010; Martinez-
Outschoorn et al., 2011).  
There are several reports indicating a suppressive role of Cav-1 in autophagy 
regulation via different mechanisms, such as insulin, oxidative stress, 
transcription factor HIF1α and NF-κB activation (Le Lay et al., 2010; 
Martinez-Outschoorn et al., 2010; Martinez-Outschoorn et al., 2011; Shiroto et 
al., 2014). A more recent study reported a direct interaction of Cav-1 with the 
Atg5-Atg12 conjugation system, indicating a suppressive role of Cav-1 in 
autophagosome formation (Chen et al., 2014d). This is generally consistent 
with our findings that disruption of lipid rafts is able to promote 
autophagosome formation (Figure 3.9 & 3.10). 
Despite of the regulatory function of Cav-1 in autophagy, lipid rafts were also 
reported to be involved in autophagy regulation via supporting the Akt-mTOR 
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signaling pathway (Cheng et al., 2006; Grider et al., 2009). The Akt-mTOR 
pathway is the main negative regulator for autophagy initiation (Jewell et al., 
2013; Zoncu et al., 2011). Lipid rafts might play a suppressive role in 
autophagy regulation through the Akt-mTOR pathway. Interestingly, in our 
study, a comparable mTOR activity in Cav-1 WT and KO cell was found; and 
with or without lipid rafts disruption by MBCD (Figure 3.8). Moreover, the 
autophagy flux induced by lipid rafts disruption was also comparable between 
the TSC2 WT (with normal mTOR activity) and TSC2 KO cells (with 
constitutively active mTOR) (Figure 3.8). Thus, our data clearly demonstrate 
that the regulatory function of lipid rafts in autophagy is independent of the 
Akt-mTOR pathway.  
Last, in contrast to the previous findings indicating a suppressive role of lipid 
rafts in autophagy regulation, some other components of lipid rafts were 
reported to promote autophagy. For example, a paradigmatic component of 
lipid rafts, GD3 ganglioside, is known to be present in both autophagosome 
(by interaction with phosphatidylinositol 3-phosphate (PtdIns3P)) and 
autolysosome (by association with LAMP1), and plays a positive role in 
autophagosome formation (Matarrese et al., 2014). It is believed that this 
ganglioside might able to support the autolysosome formation by changing 
membrane curvature and fluidity (Matarrese et al., 2014). In addition, another 
component of lipid rafts, ceramides, are known to be necessary for autophagy 
via blockage of Akt activation, upregulation of Beclin-1 or suppression of 
nutrient transporter expression (Peralta and Edinger, 2009; Scarlatti et al., 
2004; Schubert et al., 2000). However, these studies did not provide the direct 
evidence to show that the function of those lipids components in autophagy 
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regulation are lipid rafts dependent. It is possible that these lipids function 
lipid rafts independently. It remains to be further determined whether those 
individual components of lipid rafts act through lipid rafts per se in regulation 
of autophagy. In our study, we investigated the role of lipid rafts in autophagy 
by utilizing an array of well-established methods of lipid rafts disruption 
(Inder et al., 2012; Lingwood and Simons, 2007; Yamaguchi et al., 2009). 
Furthermore, we have provided the evidence showing that rescue of lipid rafts 
by either replenishment of cholesterol after MBCD disruption or Cav-1 re-
expression in Cav-1 deficient cells lead to a blockage of lipid rafts disruption-
induced autophagy (Figure 3.5). Thus, our data provide strong evidence 
demonstrating the suppressive regulatory role of lipid rafts in autophagic 
process.  
3.3.2. Lipid rafts disruption promotes autophagosome formation via 
VAMP7 
The other important finding of our study shows that lipid rafts disruption 
promotes the autophagosome formation. Since the increase of autophagic 
marker LC3-II can be caused by either induction of autophagosome formation 
and/or blockage of autolysosome degradation, the changes of this autophagic 
marker after blockage of autolysosome degradation was examined by utilizing 
lysosome inhibitors. Thus, the increased LC3-II level under lysosome 
inhibition indicates an increase of autophagosome formation. In our results, 
lipid rafts disruption by MBCD or Cav-1 deficiency significantly enhanced 
LC3-II protein level in the presence of CQ, indicating a significant increase of 
autophagosome formation (Figure 3.1, 3.3 & 3.4). In addition, our results 
showed an the increased Atg16L mobility (Figure 3.9) and colocalization 
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between Atg16 and LC3 after lipid rafts disruption (Figure 3.10), which 
provide the direct evidence of the increased autophagosome formation.  
After confirming the role of lipid rafts disruption in autophagosome formation, 
the involvement of the SNAREs protein VAMP7 was further evaluated as a 
potential downstream target in mediating autophagosome formation observed 
in cells with lipid rafts disruption (Figure 3.11 & 3.12). We found increased 
size and mobility of Strawberry-Atg16L puncta after lipid rafts disruption, 
which shares the same trends as the positive control, amino acid starvation 
(Figure 3.9). Recently, it has been reported that SNAREs protein VAMP7 
plays a critical role in Atg16L precursor homotypic fusion and the subsequent 
maturation into LC3-positive autophagosomes (Moreau et al., 2011). It is 
known that SNAREs protein are present and functionally associated with lipid 
rafts (Chamberlain et al., 2001; Fraldi et al., 2010; Lang, 2007; Xia et al., 
2004). For instance, a mutant SNARE protein (SNAP25) lost its affinity to 
lipid rafts and reduced its membrane fusion ability (Salaun et al., 2005). In this 
study, we first confirm that lipid rafts disruption leads to an increase of the 
interaction between VAMP7 and the Atg proteins (Atg5 & LC3) which is 
downstream of Atg16L homotypic fusion (Figure 3.11). Then, we observed a 
decrease of the RFP-VAMP7 and lipid Cav-1 protein (Figure 3.12), indicating 
a decreased distribution of VAMP7 on lipid rafts. These data support the 
hypothesis that the released VAMP7 protein from disrupted lipid rafts is able 
to promote the homotypic fusion of Atg16L vesicles and the following 
autophagosome formation. However, the exact molecular mechanism 
underlying the regulatory function of lipid rafts on VAMP7 still needs to be 




Chapter 4. Cav-1 deficiency and lipid rafts disruption enhance 





In the late stage of autophagy, the main organelle involved in is lysosome. 
Lysosome fuses with the outer membrane of autophagosomes to form 
autolysosomes for autophagic degradation. (Choi et al., 2013). 
Lysosomes are the cellular organelles which contain hydrolase enzymes to 
play crucial roles in cellular clearance for cellular debris, damaged organelles 
and invaded microorganisms (Lieberman et al., 2012; Saftig and Klumperman, 
2009). More than 50 soluble acid hydrolases are known to perform the 
digestive function and over 120 lysosomal membrane proteins are responsible 
for the integrity of lysosomes, lysosomal trafficking, fusion and 
intralysosomal pH. One of the most important proteins for lysosome is V-
ATPase, which generating the acidic internal pH in lysosomes. It is a proton-
pumping membrane protein and maintained by the balance of counterion 
channels (Mindell, 2012). 
Up to date, the regulatory role of lipid rafts in late stage of autophagy, 
especially for lysosomal function, has not been studied systematically. There 
are several clues indicating a potential role of lipid rafts in autophagic 
lysosomal clearance. There are data showing that accumulation of lipid rafts 
component cholesterol causes dysfunction of lysosomes (Fraldi et al., 2010; 
Liao et al., 2007a). Some important lysosome membrane proteins are 
identified to be associated with lipid rafts, such as V-ATPase, chloride 
channels CLC6/7 and LAMP-2A (Foster et al., 2003; Kaushik et al., 2006; 
Yoshinaka et al., 2004). In addition, lipid rafts are also proved to regulate 
membrane fusion mediator SNAREs which are essential for autophagosome 
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formation and lysosome- autophagosome fusion (Fraldi et al., 2010; 
Lafourcade et al., 2008; Lang, 2007; Moreau et al., 2011). 
In this part of our study, the regulatory role of lipid rafts in lysosomal function 
and the underlying mechanisms was investigated. Importantly, we provide the 
evidence supporting a direct role of lipid rafts in the V-ATPase assembly, 
which can be considered as a possible mechanism for promoted lysosomal 




4.2.1. Cav-1 deficiency and lipid rafts disruption enhance lysosomal 
function via V-ATPase assembly 
4.2.1.1. Lipid rafts disruption by Cav-1 deficiency and cholesterol depletion 
promotes lysosomal function 
Lysosomes are the key organelles responsible for autophagy degradation (Choi 
et al., 2013). Recently there is evidence demonstrating up-regulation of 
lysosomal function in the course of autophagy induced by starvation and 
mTOR inhibitors (Zhou et al., 2013). In this study, whether disruption of lipid 
rafts would affect lysosomal function was measured by the following assays: 
(i) lysosomal acidification by LysoTracker, (ii) lysosomal proteolysis by DQ-
BSA, and (iii) lysosomal cathepsin enzyme activity coupled with flow 
cytometry and confocal microscopy. First, there was significant increase in 
LysoTracker and DQ-BSA signal in Cav-1 KO MEFs when comparing to WT 
cells (Figure 4.1A), indicating enhanced lysosomal acidification and 
proteolysis activity, respectively. Second, a significant increase in lysosomal 
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cathepsin L enzyme activity in Cav-1 KO cells was detected by flow 
cytometry (Figure 4.1B) and confocal microscopy (Figure 4.3A). These data 
thus indicate that Cav-1 deficiency promotes lysosomal function. 
Consistently, a higher level of LysoTracker staining, DQ-BSA intensity and 
cathepsin L enzyme activity were found in cells treated with MBCD (Figure 
4.2). Notably, the same cholesterol replenishment which effectively recovered 
lipid rafts (Figure 3.5A & 3.5B), reversed the promoting effect of MBCD on 
lysosomal function (Figure 4.2), indicating that the effect of MBCD on 
lysosomal function is cholesterol and lipid rafts dependent. These data thus 
prove that the disruption of lipid rafts by MBCD also promotes the lysosomal 
function. 
In addition, to exclude the possibility that the increased cathepsin L activity 
after both Cav-1 deficiency and lipid rafts disruption is caused by the 
lysosomal leakage of cathepsin enzymes, the confocal microscope was used to 
observe the morphology of cathepsin L magic red staining. most of the 
cathepsin L magic red staining co-localized with lysosome, which was 
labelled by LysoTracker Green in both Cav-1 WT and KO cells and also 
before and after lipid rafts disruption by MBCD (Figure 4.3). Therefore, such 
results indicate that the increased cathepsin L caused by lipid rafts disruption 
is localized in the complete lysosome, but not due to its leakage to the cytosol. 
Thus, our data confirm that both of Cav-1 deficiency and lipid rafts disruption 





Figure 4.1 Cav-1 deficiency promotes lysosomal function. (A). Cav-1 WT 
and KO MEFs were preloaded with DQTM Red BSA (red) and co-stained with 
LysoTracker Green DND-26 (green). Then examined by confocal microscopy 
(×600). Scale bar, 10 µm. The mean florescence intensity were analyzed by 
ImageJ, means±SD were presented. (B). Cav-1 WT and KO MEFs were 
loaded with Magic RedTM Cathepsin L reagent for 15 min. Fluorescence 
intensity of 10,000 cells per sample was determined by flow cytometry using 
the BD FACS cytometer. Three independent experiments were analyzed, 
means ±SD were presented. Statistical significance for pairwise comparisons 








Figure 4.2 Lipid rafts disruption by MBCD promotes lysosomal function. 
(A). MEFs were co-stained with DQTM Red BSA and LysoTracker Green 
DND-26, then pre-treated with MBCD (5 mM) for 1 h, and then treated with 
or without CHO (30 ug/ml) for 5 h and examined by confocal microscopy 
(×600). Scale bar, 10 µm. The mean florescence intensity were analyzed by 
ImageJ, means±SD were presented. (B). MEFs were pre-treated with MBCD 
(5mM) for 1h. Then Cathepsin L enzyme activities were measured by FACS 
cytometer. Three independent experiments were analyzed, means ±SD were 
presented. Statistical significance for pairwise comparisons evaluated with a 





Figure 4.3 Cathepsin enzyme distribution does not change after 
disruption of lipid rafts. (A). Cav-1 WT and KO MEFs were co-stained with 
LysoTracker (green) and Magic Red TM Cathepsin L (red). (B) MEFs were 
treated with MBCD (5 mM) for 1 h, and co-stained with LysoTracker (green) 
and Magic Red TM Cathepsin L (red) and were then examined by confocal 
microscopy. Scale bar, 10 µm.  
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4.2.1.2. Cav-1 and lipid rafts localize on lysosomal membranes 
To assess the mechanism underlying the promoted lysosomal function after 
Cav-1 deficiency and lipid rafts disruption, a series of experiments were 
conducted. First, the LAMP-1 level after lipid rafts disruption was compared 
by both MBCD treatment and Cav-1 deficiency to confirm whether the 
enhanced lysosomal function by lipid rafts disruption is caused by the 
increasing lysosomal mass or the increased activity of a single lysosome. In 
our data, the LAMP-1 protein level was not affected by Cav-1 deficiency or 
MBCD treatment (Figure 4.4). These data suggest that the enhanced lysosomal 
function by lipid rafts disruption is caused by the increased activity of a single 
lysosome, and exclude the possibility that the observed changes of lysosomal 
functions are due to increased lysosome numbers. 
Second, the localization of lipid rafts and Cav-1 on lysosome was examined. 
The majority of lipid rafts (which was labelled by CTxB Red) was co-
localized with lysosome (labelled by Lysotracker Green) (Figure 4.5A), 
indicating a distribution of lipid rafts on lysosome. To confirm this result, we 
isolated the lysosome fraction and found that a large percentage of Cav-1 
protein was detected in the lysosome fraction (Figure 4.5B). Thus, the data 
above demonstrate a direct distribution of lipid raft and Cav-1 on lysosome 






Figure 4.4 Disruption of lipid rafts does not change the LAMP-1 protein 
level. Cav-1 WT and KO MEFs lysates were pre-treated with or without 
MBCD (5 mM) for 1 h, then collected and subjected to western blots for the 
indicated markers. Immunostaining (A) and western-blots (B) of LAMP-1 






Figure 4.5 Cav-1 and lipid rafts accumulate on lysosome membrane. (A). 
MEFs were co-stained with CTxB (red) and LysoTracker Green DND-26 
(green), then observed by confocal microscope (×600). Scale bar, 10 µm. (B). 
Lysosome fractions were collected as described in section 2.5.2. LAMP-1 was 
used as a marker for the lysosome fraction. Lysosome fractions and total cell 




4.2.1.3. Cav-1 deficiency and lipid rafts disruption promote V-ATPase 
assembly 
In order to understand the possible regulation of lipid rafts/Cav-1 on 
lysosomal function, the changes in lysosomal V-ATPase assembly was 
examined after lipid rafts disruption in Cav-1 deficient cells and in cells 
treated with MBCD. V-ATPase is known as the crucial protein complex that 
regulates the acidification process of lysosomal lumen and lysosomal 
degradation (Mindell, 2012). The V-ATPase, a proton-pumping membrane 
protein complex, is controlled by the assembly of two domains (the cytosolic 
V1 domain and the integral membrane V0 domain (Mindell, 2012). Since 
there are studies showing that lipid rafts contain V-ATPase subunits 
(Yoshinaka et al., 2004) and the existence of lipid rafts/Cav-1 on lysosome 
membrane has confirmed previously (Figure 4.5), we thus determined whether 
lipid rafts regulate the V-ATPase assembly. We used the proximity ligation 
assay (PLA) to assess the co-localization of the V0 and of V1 subunits. Indeed, 
higher level of signals was detected in cells with Cav-1 deficiency and after 
MBCD treatment (Figure 4.6A), indicating enhanced V1 translocation to 
lysosome and V-ATPase assembly in cells after lipid rafts disruption. These 
observations support the notion that disruption of lipid rafts increases the V-
ATPase V0 and V1 assembly. In addition, to confirm this results, the Cav-1 
and V-ATPase D1, a membrane-bound V0 subunit, were co-stained. The 
colocaliztion between Cav-1 and V-ATPase D1 decreased after lipid rafts 
disruption by MBCD (Figure 4.6B). Interestingly, the amino acid free 
starvation, which is a well-established promoter for lysosomal function, also 
decrease the colocalization between Cav-1 and V-ATPase D1 (Figure 4.6B). 
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These results thus indicate that the lipid rafts containing V-ATPase V0 subunit 
negatively regulate assembly of V-ATPase. In cells with lipid rafts disruption 
by MBCD or Cav-1 deficiency, the V-ATPase Vo subunit would be released 
from lipid rafts and then interact with V1 subunit. Thus, the disruption of lipid 
rafts is able to promote V-ATPase assembly, decrease lysosomal pH and 





Figure 4.6 Cav-1 deficiency and MBCD disruption promotes V-ATPase 
assembly. (A). Cav-1 WT and KO MEFs were treated with indicated 
treatments for 2 h, then fixed and followed by proximity ligation assay. 
Representative PLA images are selected and shown. (B). MEFs were treated 
with MBCD pre-treatment (5 mM, 1 h) and followed by normal or amino acid 
starvation incubation for 2 h. Then the cells were immunostained by Cav-1 
and V-ATPase D1, and observed under confocal microscope (× 600). Scale 
bar, 10 µm. Values are represented as means ±SD of three experiments. 






4.2.2. Cav-1 deficiency and lipid rafts disruption promote 
autophagosome-lysosome fusion 
The activation of lysosomal function in the course of autophagy is depending 
on autophagosome-lysosome fusion (Zhou et al., 2013). Here the effect of 
lipid rafts on this fusion process was assessed by using the L929 cells with 
stable transfection of tfLC3 (mRFP-GFP tandem fluorescent‑tagged LC3). In 
this cells, the RFP is more resistant than GFP to the acidic lysosome 
environment. Therefore, RFP-positive/GFP-negative puncta indicate the 
formation of autolysosome following the fusion of autophagosome (containing 
LC3) and lysosome (to form an acidic autolysosome) (Kimura et al., 2007). 
The increased RFP puncta after MBCD treatment indicates a positive effect of 
lipid rafts disruption on autophagosome-lysosome fusion (Figure 4.7A & B). 
In cells treated with Baf (for 15 h), all of the puncta were double positive for 
GFP and RFP, indicating a complete blockage of autophagosome-lysosome 
fusion (Figure 4.7C & D). Removal of Baf from the cell culture medium 
would eliminate the blockage and resume the autophagosome-lysosome fusion 
process (Fraldi et al., 2010). After Baf removal, autophagosomes (both GFP 
and RFP positive) would proceed with lysosome fusion to form autolysosome. 
Therefore, by comparing the ratio of GFP/RFP signals after Baf removal we 
are able to evaluate the autophagosome-lysosome fusion process. In 
comparison to control cells, MBCD markedly reduced the relative ratio of 
GFP/RFP, indicating a higher rate of autophagosome-lysosome fusion and 
autolysosome formation in MBCD-treated cells (Figure 4.7C & D). Notably, 
the effect of MBCD was even more evident than the positive control, amino 









Figure 4.7 Disruption of lipid rafts promotes autophagosome-lysosome 
fusion. (A). The tfLC3-L929 cells were pretreated with or without MBCD (5 
mM) for 1 h, then incubated in both normal DMEM and amino acid free 
medium for 2 h. Cells were examined using a confocal microscope (×600). (B). 
Statistical analysis of the figures in panel (A) by the average RFP fluorescence 
per cell. Values are represented as means ±SD of three experiments. (C). The 
tfLC3-L929 cells were treated by Baf (50 nM) for 15 h. Then change the 
medium to indicated treatments and observed under confocal microscopy at 
each time (3,6 and 9 h). Representative data from 9h treatment were presented. 
Scale bar, 10 µm. (D). Statistical analysis of GFP/RFP ratio. The rate of 
autophagosome maturation were measured by green/red fluorescence ratio 
(Relative Ratio of GFP/RFP) of indicated treatments at each time (3, 6 and 9 h) 
after Baf removal (0). The ratio of GFP/RFP was normalized to the value at 
T0. Values are represented as means ±SD of three experiments. Statistical 







4.3.1. The regulatory role of Cav-1 and lipid rafts on lysosome 
It has been reported that the lipid rafts and Cav-1 are present in various 
organelles, including mitochondria, endoplasmic reticulum, trans-Golgi 
network, lipid droplets, as well as lysosome (Lingwood and Simons, 2010; 
Mundy et al., 2012; Robenek et al., 2004; Schlegel et al., 2001; Sonnino and 
Prinetti, 2013; Waheed and Freed, 2010). For instance, the phosphorylation of 
Cav-1 is proved to be critical for ER retention (Schlegel et al., 2001). More 
importantly, the existence of Cav-1 in lysosome and the associations between 
several important lysosomal proteins (including V-ATPase, chloride channels 
and lysosome associated membrane protein type 2A) suggests the possible 
function of Cav-1 and lipid rafts in lysosome (Foster et al., 2003; Kaushik et 
al., 2006; Lafourcade et al., 2008; Yoshinaka et al., 2004). In our study, the 
colocalization between lipid rafts marker and lysosome marker and the 
presence of Cav-1 in lysosome fraction confirmed the existence of both Cav-1 
and lipid rafts on lysosome membrane (Figure 4.4). These results raise the 
possibility of a direct regulatory role of Cav-1 and lipid rafts in lysosomal 
function. 
In our study, enhanced lysosomal function after lipid rafts disruption was 
found by cholesterol depletion and Cav-1 deficiency (Figure 4.1-4.3), 
indicating a suppressive role of Cav-1 and lipid rafts in lysosomal function. 
This is generally consistent with several previous findings. For example, an 
accumulation of lipid rafts or so-called 'cholesterol-enriched region' on late 
endosome/lysosome was found in some lysosomal storage diseases (Fraldi et 
al., 2010; Simons and Gruenberg, 2000). Moreover, for CMA, enhanced 
105 
 
lysosomal function was found in the lysosomes containing a mutant LAMP-
2A that is unable to move into the lipid rafts region on lysosomal membrane, 
indicating a general suppressive function of lipid rafts on lysosomal function 
(Kaushik et al., 2006).  
One of the characteristic components of lipid rafts, cholesterol, has also been 
reported to be involved in autophagy regulation. In NPC deficient cells, the 
accumulation of cholesterol in lysosome was reported to inhibit autophagy 
(Ishibashi et al., 2009). And abnormal accumulation of cholesterol was also 
known to inhibit lysosomal functions via SNARE proteins (Fraldi et al., 2010). 
Our results are generally consistent with these studies. 
Intriguingly, lysosome itself also has a regulatory function on lipid rafts. For 
instance, degradation of Cav-1 has been proved to be lysosome-dependent 
(Hayer et al., 2010). Thus, the increased lysosomal function will lead to an 
decrease of Cav-1 protein level. Interestingly, our data prove that loss of Cav-
1 and disruption of lipid rafts will further increase the lysosomal function. 
Thus, our data suggest the presence of a potential positive feedback loop 
between Cav-1/lipid rafts and lysosomal function, which still need further 
study.  
4.3.2. Lipid rafts disruption enhances V-ATPase assembly 
The acidic internal pH in lysosomes is generated by the action of a V-ATPase, 
a proton-pumping membrane protein and maintained by the balance of 
counterion channels (Mindell, 2012). Based on evidence of the distribution of 
V-ATPase on lipid rafts (Foster et al., 2003; Kaushik et al., 2006; Lafourcade 
et al., 2008; Yoshinaka et al., 2004), we then focused our attention on the role 
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of lipid rafts and Cav-1 on V-ATPase. The V-ATPase complex consists of two 
domains, the membrane-bound V0 domain and a cytosolic V1 domain. The 
assembly status of the V1 and V0 domains is the main determinant of the 
enzymatic activity of V-ATPase (Mindell, 2012). In our study, we found that 
lipid rafts disruption by MBCD treatment and Cav-1 deficiency is able to 
promote assembly of V-ATPase (Figure 4.6A), indicating the involvement of 
V-ATPase assembly in the lysosomal function regulated by lipid rafts.   
Next, to confirm whether Cav-1 and lipid rafts hinder the assembly process of 
the V-ATPase complex, the colocalization between lipid rafts and V-ATPase 
V0 subunit was detected. As expected, colocalization between Cav-1 and V-
ATPase D1, a V0 subunit was decreased (Figure 4.6B). Interestingly, similar 
results were found in cells under amino acid starvation. These results are 
consistent with the previous reports showing the distribution of V-ATPase in 
lipid rafts fraction (Foster et al., 2003; Kaushik et al., 2006; Lafourcade et al., 
2008; Yoshinaka et al., 2004).  
4.3.3. Lipid rafts disruption promotes autophagosome-lysosome fusion 
The mRFP-GFP tagged LC3 was utilized as a tool to detect the 
autophagosome-lysosome fusion after lipid rafts disruption by cholesterol 
depletion. As expected, these data indicating a promoted autophagosome-
lysosome fusion after lipid rafts disruption (Figure 4.7). This is generally 
consistent with the previous finding indicating that the abnormal accumulation 
of cholesterol-enriched region in lysosomal membranes impairs lysosome 
fusion (Fraldi et al., 2010). 
107 
 
A recent study has demonstrated the functional activation of lysosome in the 
course of autophagy, a process depending on both mTORC1 inhibition and 
autophagosome-lysosome fusion (Zhou et al., 2013). Thus, in addition to the 
enhanced V-ATPase assembly, which promotes lysosomal function directly, 
the increased autophagosome-lysosome fusion also may play an important role 






Chapter 5. Autophagy mediated by Cav-1 deficiency and lipid rafts 






Both Cav-1 and lipid rafts have been reported to both positively and 
negatively regulate tumor development (Galbiati et al., 2001; Patra, 2008). 
There is emerging evidence demonstrating the tumor suppression functions of 
Cav-1 in several types of cancer, especially in breast cancer. For instance, 
expression of oncogenes (such as v-abl and H-ras) leads to a significant 
decrease in Cav-1 protein and mRNA levels (Engelman et al., 1997). Loss of 
Cav-1 induces cellular transformation through the activation of the p42/44 
MAP kinase cascade and development of an unusual growth pattern with 
increased phospho-ERK1/2 independent of EGF (Galbiati et al., 1998; Sotgia 
et al., 2006). Consistently, over-expression of Cav-1 was sufficient to decrease 
cell proliferation and tumor size in vivo (Engelman et al., 1997). 
In breast cancer, a large percentage of patients were found to be deficient in 
Cav-1 expression (Sloan et al., 2009). Several human breast cancer cell lines 
have also been shown to display a decreased Cav-1 expression level compared 
to benign mammary epithelial cells (Bai et al., 2012). Moreover, about 35% 
breast cancer cases contained mutant Cav-1 (Li et al., 2006). For example, a 
dominant negative mutant Cav-1 (P132L) has been identified in ER-positive 
patients with well-differentiated breast cancer (Lee et al., 2002; Mercier et al., 
2009b). On the other hand, there are studies indicating that deficiency of Cav-
1 expression in breast cancer stromal cells is closely associated with poor 
clinical outcomes (Ma et al., 2013b; Sloan et al., 2009; Witkiewicz et al., 2010; 
Witkiewicz et al., 2009). A possible mechanism for the suppressive function 
of Cav-1 in tumor stromal cell is to control the tumor microenvironment 
(Bonuccelli et al., 2010; Pavlides et al., 2010). Although the studies discussed 
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above indicate a tumor suppressive role for Cav-1, there is still conflicting 
evidence indicating a promoting role of Cav-1. For instance, Cav-1 expression 
in breast tumor stroma is known to promote shown to increase tumor invasion 
and metastasis via biomechanical remodeling (Goetz et al., 2011). Therefore, 
the biological role of Cav-1 and lipid rafts in breast cancer and its molecular 
mechanisms remains largely elusive. 
The role of autophagy in cancer is rather complex and also remains highly 
controversial. At present, autophagy is widely considered as a double-edged 
sword in cancer: during the initiation stage of tumorigenesis and oncogenic 
transformation processes, autophagy functions as a tumor suppressor 
mechanism; and on the contrary, once the tumor is formed, autophagy in the 
tumor cells will provide a survival advantage to resist cell death induced by 
cancer therapeutic agents (Kimura et al., 2013; Shen and Codogno, 2011; Shen 
and Codogno, 2012). Therefore, suppression of autophagy utilizing chemical 
inhibitors can be considered as a novel strategy for cancer treatment 
(Kimmelman, 2011; Kimura et al., 2013; Maycotte and Thorburn, 2011; Notte 
et al., 2011). One potential issue for the autophagy targeting therapy is that so 
far there are no clear clinical indicators or biomarkers for the suitability of 
caners or patients for this therapy. Thus, the identification of such biomarkers 
or indicators will provide advantages for these cancer therapeutic approaches 
by suppression of autophagy. 
In this part of study, the evidence revealing decreased Cav-1 and lipid rafts 
level in breast cancer cell lines and cancerous tissues was provided. In 
addition, in MCF7 cells (known to be Cav-1 deficient), re-expression of Cav-1 
rescues the lipid rafts level, suppresses autophagy and sensitizes the cells 
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death against starvation stress. Thus, our results indicate that in breast cancer 
cells, the deficiency of Cav-1 and lipid rafts might be used as a survival 
mechanism against cellular stress via autophagy. 
 
5.2. RESULTS 
5.2.1. Autophagy mediated by Cav-1 deficiency and lipid rafts disruption 
promotes cell survival under starvation  
5.2.1.1. Cav-1 deficiency promotes cell survival under starvation stress 
One important physiological role of autophagy is to prolong cell survival 
under starvation by recycling cytoplasmic components to provide the essential 
nutrients needed (Lum et al., 2005; Mizushima, 2007; Onodera and Ohsumi, 
2005; Raben et al., 2008). Therefore, it is possible that the cells with disrupted 
lipid rafts, such as loss of Cav-1, can use autophagy as a mechanism for cell 
survival under starvation. Here, the cell viability was examined by 
morphological changes and the PI exclusion assay to test if lipid rafts 
disruption-induced autophagy would have any impact on cell death. 
We observed that Cav-1 KO MEFs were more resistant to amino acid 
starvation when comparing to WT MEFs by morphological changes and the PI 
exclusion assay coupled with flow cytometry (Figure 5.1), indicating that the 






Figure 5.1 Cav-1 deficiency promote cell survival under starvation stress. 
(A) Morphological changes of Cav-1 WT and KO MEFs under full medium or 
amino acid starvation for 48 h. (B) The percentage of dead cells treated as 
described in panel (A) was measured with the PI exclusion assay coupled with 
flow cytometry. Values are represented as means ±SD of three experiments. 






5.2.1.2. Disruption of lipid rafts by MBCD treatment promote cell survival 
under starvation stress via autophagy induction 
To confirm the role of lipid rafts disruption-mediated autophagy in cell 
survival under starvation, the effect of MBCD treatment on cell death under 
starvation was further examined. 
First, MBCD treatment alone did not have any effect on cell viability under 
normal condition (Figure 5.2A & 5.2C). However, we observed a significant 
protective effect of MBCD pre-treatment on cell viability after amino acid 
starvation based on both morphological changes and PI exclusion assay 
detected by flow cytometry (Figure 5.2). This is consistent with our earlier 
findings that the Cav-1 deficiency promotes cell survival after starvation stress 
(Figure 5.1). 
Second, to confirm whether the protective effect caused by lipid rafts 
disruption is autophagy-dependent, the effect of MBCD treatment was 
detected in cells with depletion of an essential autophagic gene, Atg5. MBCD 
treatment enhanced both basal and starvation-induced autophagic flux level 
only in Atg5 WT MEFs, but not in Atg5 KO MEFs (Figure 5.2B). As 
expected, while depletion of cholesterol by MBCD is effective in protecting 
against starvation-induced cell death in Atg5 WT MEFs, MBCD did not offer 
any protection against starvation-mediated cell death in Atg5 KO cells. The 
Atg5 KO MEFs were much more susceptible to cell death under starvation 
(Figure 5.2A & 5.2C). These results thus indicate that the protective effect by 





Figure 5.2 MBCD disruption promotes cell survival under starvation 
stress via autophagy induction. (A). MBCD protects cell death in Atg5 WT 
cells after amino acid starvation (AA-). Atg5 WT and KO MEFs were pre-
treated with MBCD (5 mM) for 1 h, following by amino acid starvation. (B). 
WT and Atg5 KO MEFs were pretreated with or without MBCD (5 mM) for 1 
h, then incubated in the presence or absence of CQ (20 µM). The cell lysates 
were collected for western blot analysis. (C) The cells with same treatment as 
panel (A), the percentage of dead cells was measured with the propidium 
iodide (PI) exclusion assay coupled with flow cytometry. Statistical 
significance for pairwise comparisons evaluated with Student’s t-test.  
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5.2.2. Cav-1 expression level is reduced in some human breast cancer 
cells 
Data from earlier part of our study demonstrate that lipid rafts disruption 
promotes autophagy. Since autophagy is widely considered as a tumor 
suppressive mechanism, the hypothesis is that Cav-1 and lipid rafts are 
associated with cancer development via modulation of autophagy. We 
therefore measured the Cav-1 protein level in a set of different breast cancer 
cell lines and a non-tumorigenic MCF10A. 
Among them, ZR 75-1, SK-BR3 and MCF7 had lower level of Cav-1 
expression, while the Cav-1 protein level in MDA-MB-231, MDA-MB-436 
were found to be higher, similar to MCF10A cells (Figure 5.3A). Such results 
are generally consistent with the earlier reports with regards to Cav-1 
expression in breast cancer cells (Bai et al., 2012). Therefore two breast cancer 
cell lines MDA-MB-231 and MCF7 were chosen to elucidate the function of 
Cav-1 in autophagy and cell survival. The mRNA level of Cav-1 was found to 
be consistent with the protein level in these two cell lines (Figure 5.3B). CTxB 
and filipin staining were compared as direct evidence for lipid rafts levels. 
Consistent with Cav-1 expression level, MDA-MB-231 cells with high Cav-1 
expression had a relatively higher CTxB and filipin level when comparing to 
MCF7 cells (Figure 5.3C & 5.3D). These data thus suggest that Cav-1 





Figure 5.3 Cav-1 expression level is reduced in human breast cancer cells. 
(A). The lysates of MCF-10A and 5 breast cancer cell lines were 
immunoblotted with indicated markers. (B). Quantitative real-time RT-PCR 
analysis of mRNA levels of Cav-1 in the MDA-MB-231 and MCF7 cells. The 
amount of Cav-1 expression in MDA-MB-231 cells was regarded as 100% (C-
D). MDA-MB-231 and MCF7 cells were stained by rafts marker CTxB (C) 




5.2.3. Re-expression of Cav-1 in MCF7 recovers lipid rafts and 
suppresses autophagy and lysosomal function 
5.2.3.1. Re-expression of Cav-1 in MCF7 recovers lipid rafts level 
In this part of our study, we utilized a stable cell line in which the MCF7 cells 
were reconstituted with Cav-1 to examine the function of Cav-1 in lipid rafts 
and autophagy regulation. 
The lipid rafts level was compared between EGFP and EGFP-Cav-1 re-
constituted MCF7 cells. As expected, the lipid rafts markers CTxB and filipin 
staining were significantly increased in MCF7 cells with Cav-1 constitution 
comparing to those with the EGFP control vector (Figure 5.4), indicating the 
recovery of lipid rafts level by Cav-1 re-expression. In addition, most of the 





Figure 5.4 Re-expression of Cav-1 in MCF7 recovers lipid rafts level. 
MCF7 cells with stable expression of EGFP and EGFP-CAV-1 were stained 
by rafts marker CTxB (A) and Filipin (B) and observed by confocal 
microscope (X600). Scale bar, 10 µm. To get a comparable image, the power of 





5.2.3.2. Re-expression of Cav-1 in MCF7 blocks autophagy flux and decreases 
lysosomal function 
Here the autophagy level was compared between the EGFP and EGFP-Cav-1 
expression MCF7 cells. The autophagy marker LC3-II level was decreased in 
MCF7 cells with exogenous expression of Cav-1 with or without CQ 
treatment (Figure 5.5A), being consistent with the earlier notion that Cav-1 
negatively regulates autophagy. Moreover, expression of Cav-1 also led to 
reduced LysoTracker staining (Figure 5.5B), indicating a decreased lysosomal 
acidification in the Cav-1 reconstituted cells. Thus, our data confirm the 
critical role of Cav-1 in autophagy and lysosomal regulation via lipid rafts. 
5.2.3.3. Re-expression of Cav-1 sensitizes the MCF7 cells to cell death 
induced by starvation  
To confirm the implication of Cav-1-mediated autophagy in stress responses, 
the cell viability was compared between EGFP and EGFP-Cav-1 expression 
MCF7 cells. An increased cell death in the EGFP-Cav-1 expression MCF7 
cells were detected after starvation, indicating that the re-expression of Cav-1 
sensitized the MCF7 cells to cell death induced by amino acid starvation 





Figure 5.5 Re-expression of Cav-1 in MCF7 blocks autophagy flux and 
decreases lysosomal function. (A). MCF7 cells with stable expression of 
EGFP and EGFP-CAV-1 were treated with CQ (20 μM) for 2 h, then the cell 
lysates were blotted to indicated markers. (B) MCF7 cells with stable 
expression of EGFP and EGFP-CAV-1 were incubated with LysoTracker (red) 
and observed on confocal microscopy (×600). Scale bar, 10 µm. To get a 
comparable image, the power of green laser was reduced for EGFP expressing 




Figure 5.6 Re-expression of Cav-1 sensitizes the MCF7 cells to cell death 
induced by starvation stress. (A). EGFP and EGFP-CAV-1 MCF7 cells were 
treated with or without amino acid after 48 h, then stained with PI. The PI 
staining was observed under fluorescent microscope. (B) The percentage of 
PI-positive cells were counted and analyzed. Three independent experiments 
were analyzed, means±SD were presented. Statistical significance for pairwise 




5.2.4. Downregulation of Cav-1 with enhanced autophagy in human 
breast cancer tissues 
In order to understand the pathological implication of Cav-1 and lipid rafts in 
human breast cancer, the Cav-1 mRNA and protein levels in 7 pairs of breast 
cancer and their adjacent normal tissues were analyzed and compared. As 
shown in Figure 5.7A, we found marked down-regulation for Cav-1 protein 
levels in the cancerous tissues. Similarly, the mRNA level of Cav-1 was 
significantly lower or undetectable in the cancerous tissues (Figure 5.7B). 
Consistent results were also found by immunohistochemical staining of 
paraffin-embedded tissue samples (Figure 5.7C & 5.7D). In all of the samples, 
a lower level of Cav-1 in breast tumor tissues was detected by immunostaining 
(one representative pair was shown in Figure 5.7C and the statistical analysis 
of the semi-quantification of the Cav-1 level in 7 pairs of tissue samples were 
shown in Figure 5.7D). Since Cav-1 is associated with autophagy as shown 
earlier, the autophagic markers in those human breast cancer and adjacent 
tissue samples was further analyzed and compared. As shown in Figure 5.7A, 
among the 7 pairs tested, LC3-II level was increased in cancerous tissues in 4 
pairs of the samples (#11, #20, #19 & #86). And the autophagy substrate p62 
protein level is correspondingly reduced in all the cancerous tissues, indicating 
a promoted autophagy level. Taken together, these data suggest that down-









Figure 5.7 Downregulation of Cav-1 with enhanced autophagy in human 
breast cancer tissues. (A). The lysates of 7 pairs of tumors and their adjacent 
normal tissue samples were immunoblotted with indicated markers.(B). 
Quantitative real-time RT-PCR analysis of mRNA levels of Cav-1 in the 7 
pairs of tumor and their adjacent normal tissue samples. The amount of Cav-1 
expression in the normal tissue of first pair was regarded as 100%. (C). 
Immunostaining of Cav-1 in Paraffin embedded section from breast tumor and 
their adjacent normal samples. Samples was immuno-stained with anti-Cav-1, 
then counter stained with hematoxylin (400X). The tissues morphology was 
confirmed by H&E staining (200X). (D) The statistical analysis of 7 pairs of 
breast tumor and adjacent normal samples. The intensities of Cav-1 proteins 
were quantified using the Motic Images Advanced software, followed by 






5.3.1. Lipid rafts disruption and cell death 
Lipid rafts and Cav-1 are reported to be implicated in cell death, mainly via 
the modulation of distribution of cell death receptors in lipid rafts located in 
plasma membrane (George and Wu, 2012). For example, several drugs are 
reported to promote apoptosis via recruiting pro-apoptotic proteins, such as 
Fas, to lipid rafts (Gajate et al., 2009). Here our data prove that lipid rafts also 
control cell death and survival via regulation of autophagy (Figure 5.1, 5.2 & 
5.6). Disruption of lipid rafts promotes autophagy which then provides pro-
survival advantages to cells or induces resistance to cell death stimulated by 
stress. Thus, the effect of lipid rafts on autophagy should be taken into 
consideration for the lipid rafts-targeting drugs for cancer treatment, such as 
Edelfosine, Avicin D and Resveratrol (George and Wu, 2012).  
5.3.2. Lipid rafts disruption-induced autophagy is an important cell 
survival mechanism for breast cancer cells against starvation  
Autophagy has been well established as a cell survival mechanism under stress 
conditions such as starvation (Lum et al., 2005; Mizushima, 2007; Onodera 
and Ohsumi, 2005; Raben et al., 2008). Consistently, in this study, it is found 
that autophagy mediated by Cav-1 deficiency or lipid rafts disruption by 
MBCD treatment protects against cell death induced by starvation (Figure 5.1, 
5.2 & 5.6). The pro-survival function of autophagy is implicated in cancer 
development. At present, it has been widely recognized that autophagy serves 
as a double-edged sword in cancer: autophagy functions as a tumor suppressor 
during the initiation stage of cancer progression; and on the contrary, once the 
tumor is formed, tumor cells can use autophagy as survival mechanism to 
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resist cell death induced by cancer therapeutic agents (Kimura et al., 2013; 
White, 2012; White and DiPaola, 2009). Based on this understanding, 
inhibition of autophagy using chemical inhibitors is a novel approach for 
cancer patients (Kimmelman, 2011; Kimura et al., 2013; Maycotte and 
Thorburn, 2011; Notte et al., 2011). Cav-1 is believed to possess tumor 
suppression function in several types of cancer, especially in breast cancer, 
based on observations that Cav-1 is down-regulated or with loss function 
mutants in the breast cancer cells (Bai et al., 2012; Li et al., 2006; Sloan et al., 
2009; Witkiewicz et al., 2010). Moreover, in breast cancer, lipid rafts and 
Cav-1 are known to be crucial for some key processes, including apoptosis, 
growth factors receptor signalling and several other important signal pathways 
(Chen and Resh, 2002; Freeman et al., 2007; Gajate and Mollinedo, 2005). For 
instance, the oncogenic proteins EGFR, HER2 and IGF are associated with 
lipid rafts (Chinni et al., 2008; Freeman et al., 2007; Manes et al., 1999). 
Targeting lipid rafts may have anti-cancer effect by promoting the 
internalization and degradation of those oncogenic proteins (Lee et al., 2014). 
In this study, downregulated Cav-1 levels were found in both breast cancer 
cell lines and cancerous tissues (Figure 5.3 & 5.7). Our data also indicate that 
a higher autophagy level correlates with lower Cav-1 expression in the breast 
cancer tissues (Figure 5.7). Therefore, breast cancer cells use autophagy as a 
pro-survival mechanism to resist cell death, especially those cancer cells with 
lower level of Cav-1 and impaired lipid rafts function. The results presented in 
this study also suggest a possible explanation for the poor clinical outcomes of 
those breast cancer patients with Cav-1 deficiency, as reported previously (Ma 
et al., 2013b; Sloan et al., 2009; Witkiewicz et al., 2010; Witkiewicz et al., 
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2009). At present, there is no reported biomarker in selection of cancer 
patients for autophagy-targeted chemotherapies. Thus, our study indicates that 
those breast cancer patients with Cav-1 deficiency might be more applicable to 











6.1. CAV-1 AND LIPID RAFTS IN EARLY STAGE OF AUTOPHAGY 
Our results are generally consistent with several earlier studies in which Cav-1 
and lipid rafts are able to negatively regulate autophagy, via multiple 
mechanisms (Chen et al., 2014d; Cheng et al., 2006; Martinez-Outschoorn et 
al., 2010; Martinez-Outschoorn et al., 2011). First, in adipocytes, Cav-1 
deficiency was reported to suppress insulin and lipolytic responses, which then 
leads to autophagy induction (Le Lay et al., 2010). Second, loss of Cav-1 
promotes autophagy via enhanced oxidative stress and NF-κB activation 
(Martinez-Outschoorn et al., 2011; Shiroto et al., 2014). Third, a recent report 
provided direct evidence to show a competitive interaction between Cav-1 and 
Atg5-Atg12 system, via which it suppresses the formation and function of 
Atg5-Atg12 complex in lung epithelial cells (Chen et al., 2014d). In contrast, 
some components of lipid rafts were reported to promote autophagy. For 
instance, a paradigmatic component of lipid rafts, GD3 ganglioside, plays a 
positive role in autophagosome formation (Matarrese et al., 2014). In addition, 
another components of lipid rafts, ceramides, have also been implicated in 
autophagy induction via blockage of Akt activation, upregulation of Beclin-1 
or suppression of nutrient transporter expression (Peralta and Edinger, 2009; 
Scarlatti et al., 2004; Schubert et al., 2000). Notably, these studies did not 
provide the direct evidence to show the functions of those lipids in autophagy 
regulation are lipid rafts-dependent.  
Our results demonstrate the interaction between VAMP7 and Cav-1 (Figure 
3.12), which is consistent with the previous finding showing the existence of 
VAMP7 in lipid rafts microdomains (Lafont et al., 1999). The role of lipid 
rafts in SNAREs regulation remains elusive. On one hand, the association 
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between SNAREs and lipid rafts might be essential for SNARE functioning, 
indicating a positive regulatory effect of lipid rafts on SNAREs (Bacia et al., 
2004; Chamberlain and Gould, 2002; Tsai et al., 2007). On the other hand, 
SNAREs function is reported to be impaired by cholesterol accumulation 
(Fraldi et al., 2010). Interestingly, a mutant SNARE protein (SNAP25) with an 
increased affinity to lipid rafts reduces its ability to support membrane fusion 
during exocytosis, which indicating a suppressive role of lipid rafts played in 
SNAREs function (Salaun et al., 2005). As shown in Figure 6.1, our results 
demonstrate that the release of VAMP7 from lipid rafts after disruption 
promotes the association between VAMP7 and Atg proteins, indicating a 
possible negative regulatory role of lipid rafts in VAMP7 function in 
homotypic fusion of Atg16L containing vesicles. This is generally consistent 
with the previous findings showing the involvement of VAMP7 activity in the 
homotypic fusion of Atg16L and the following autophagosome formation 
process (Moreau et al., 2011). 
 
Figure 6.1 Model of the regulatory role of lipid rafts and Cav-1 in early 




In addition, this study also provides the evidence to show that caveolae is not 
involved in autophagy mediated by lipid rafts disruption. Caveolae and planar 
lipid rafts are two major types of lipid rafts (Sonnino and Prinetti, 2013). They 
are structurally and functionally distinct, while Cav-1 has been well-
established to play a critical role in the structure and function of caveolae. At 
present, there is evidence demonstrating that Cav-1 is also involved in planar 
lipid rafts, possibly through cholesterol regulation (Bosch et al., 2011; 
Levental et al., 2010). Unlike caveolae which is mainly present in plasma 
membrane , the planar lipid rafts distribute widely in various cellular 
membrane systems, including intracellular membranes (Sonnino and Prinetti, 
2013). 
In this study, we demonstrate that the inducing effect of autophagy by lipid 
rafts disruption is caveolae-independent, based on the observations that 
depletion of another critical caveolae regulator PTRF did not affect autophagy 
(Figure 3.7). Furthermore, lipid rafts were found to be distributed in lysosomal 
membranes and the accumulation of Cav-1 on lysosome fraction (Figure 4.5). 
Thus we provide the evidence supporting the possibility that it is the Cav-1-
dependent planar lipid rafts localized at lysosomes, but not the membrane 
bound caveolae, modulate the lysosomal function and autophagy. Importantly, 
these results are generally consistent with the earlier studies showing the role 
of cholesterol in lysosome regulation and the existence of Cav-1 in 
autophagosome (Chen et al., 2014d; Fraldi et al., 2010). PTRF was reported to 
stabilize Cav-1 protein at plasma membrane, and deficiency of PTRF may lead 
to the internalization and degradation of Cav-1 (Hill et al., 2008; Mundy et al., 
2012). Therefore, although loss of PTRF promotes the degradation of Cav-1, 
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as shown in Figure 3.7, the amount of lysosome-distributed Cav-1 might not 
be decreased. This may explain why PTRF deficiency down-regulates the 
amount of Cav-1 protein, but has no effect on autophagy. 
6.2. CAV-1 AND LIPID RAFTS IN LATE STAGE OF AUTOPHAGY 
In our attempt to understand the molecular mechanisms underlying the 
regulatory role of Cav-1 and lipid rafts in late stage of autophagy, we focused 
our attention on lysosomes. The roles of lipid rafts in different cellular 
organelles have been reported previously. For instance, the lipid rafts adaptor 
p18 is known to control endosome dynamics by anchoring the MEK–ERK 
pathway to late endosomes (Nada et al., 2009). The lipid rafts are also known 
to play an important role in trans-Golgi network for membrane trafficking 
(Klemm et al., 2009). Furthermore, several lysosome membrane proteins are 
known to associate with lipid rafts, such as V-ATPase, chloride channels 
CLC6/7 and LAMP-2A, suggesting a possible role of lipid rafts in regulation 
of lysosomal functions (Foster et al., 2003; Yoshinaka et al., 2004). Here, we 
provide clear evidence to show the involvement of lipid rafts in regulation of 
lysosomal function. Disruption of lipid rafts (by MBCD treatment) or loss of 
Cav-1 enhances lysosomal function via promotion of V-ATPase assembly 
(Figure 4.1-4.6). It has been reported earlier that Cav-1 and lipid rafts localize 
on late endosome and lysosome membranes (Mundy et al., 2012), while their 
functions on such organelles are not well understood. In some lysosomal 
storage diseases, a higher level of lipid rafts is found on late endosome or 
lysosome (Hayer et al., 2010; Simons and Gruenberg, 2000). A recent study 
also demonstrated that the abnormal accumulation of 'cholesterol-enriched 
region' lead to lysosomal disease (Fraldi et al., 2010). Such observations thus 
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suggest the possibility that lipid rafts may act as a negative regulator of 
lysosomal function. Data from our study are indeed supportive to such a 
hypothesis. It is thus believed that modulation of Cav-1 and lipid rafts is able 
to regulate lysosomal function. Interestingly, it has been reported that Cav-1 
can be degraded in acidic lysosomal or late endosome (Hayer et al., 2010). 
Here, we showed that the loss of Cav-1 will promote the lysosomal function, 
indicating a positive feedback loop between Cav-1 and lysosomal function. 
In order to understand the molecular mechanisms underlying the regulatory 
roles of Cav-1 and lipid rafts on lysosomal function, we examined the changes 
of V-ATPase assembly. V-ATPase is the main determinant in lysosome 
acidification and functions (Mindell, 2012). The assembly of V1 and V0 
domains is critical for its enzymatic activity (Kane, 2012; Mindell, 2012) and 
the V-ATPase complex has been reported to localize to lipid rafts (Yoshinaka 
et al., 2004). We found that deficiency of Cav-1 and disruption of lipid rafts 
by MBCD promote V-ATPase assembly (Figure 4.6A), suggesting that Cav-1 
and lipid rafts may hinder the assembly process of the V-ATPase complex. In 
addition, we have the evidence that both lipid rafts and amino acid starvation 
lead to the decreases of the colocalization between Cav-1 and V-ATPase V0 
subunit (Figure 4.6B), thus providing a possible explanation for the enhanced 
V-ATPase assembly with Cav-1 deficiency and lipid rafts disruption. As 
shown in Figure 6.2, the membrane bonded V0 subunit localized in lipid rafts 
and might interact with Cav-1 directly; and lipid rafts and Cav-1 might prevent 
the V0 and V1 subunits assembly process. Thus, disruption of lipid rafts will 
release the V0 subunits and promote their interaction with the V1 subunits. 
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However, this hypothesis still need to be further confirmed and how exactly 
the lipid rafts regulate the V-ATPase assembly remains to be further clarified. 
In addition, we also provide the evidence indicating a promoting effect of lipid 
rafts on autophagosome-lysosome fusion. Our findings are generally 
consistent with previous reports that an abnormal accumulation of cholesterol 
blocks autophagosome-lysosome fusion via regulation of membrane fusion 
mediator SNAREs proteins (Fraldi et al., 2010; Lang, 2007; Moreau et al., 
2011). Moreover, lipid rafts are also known to be critical for the regulation of 
SNAREs (Bacia et al., 2004; Chamberlain and Gould, 2002; Fraldi et al., 2010; 
Tsai et al., 2007), which raising a potential explanation for the increased 
autophagosome-lysosome fusion after lipid rafts disruption. 
 
Figure 6.2 Model of the regulatory role of lipid rafts and Cav-1 in late 
stage of autophagy.  
 
6.3. CAV-1 AND LIPID RAFTS IN BREAST CANCER REGULATION 
Our data indicate the disruption of lipid rafts or deficiency of Cav-1 protect 
cell from amino acid starvation-induced cell death via promoting autophagy 
(Figure 5.1, 5.2 & 5.6). This is generally consistent with the previous 
literatures indicating the implication of lipid rafts and Cav-1 in cell death 
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regulation (George and Wu, 2012). However, unlike previous studies using the 
cell death receptors regulation as a mechanism for the regulation of lipid rafts 
and Cav-1 in cell death and survival control (George and Wu, 2012), our data 
firstly demonstrate the importance of autophagy in this regulation (Figure 5.2). 
Autophagy is known to be a cell survival mechanism under stress conditions 
such as starvation (Lum et al., 2005; Mizushima, 2007; Onodera and Ohsumi, 
2005; Raben et al., 2008). This pro-survival advantage of autophagy can be 
used by cancer cells against adverse environment stress (White, 2012). 
Consistently, our data also prove the dependency of autophagy in the 
protection provided by lipid rafts disruption under starvation conditions 
(Figure 5.2). 
Our data also provide evidence demonstrating the down-regulated Cav-1 
levels in both breast cancer cell lines and cancerous tissues (Figure 5.3 & 5.7), 
which is consistent with the previous studies reporting down-regulated or loss 
functional Cav-1 in breast cancer (Bai et al., 2012; Li et al., 2006; Sloan et al., 
2009; Witkiewicz et al., 2010). 
Importantly, our data also find a higher autophagy level correlating with lower 
Cav-1 expression in the breast cancer tissues (Figure 5.7). Therefore, our data 
here indicate that autophagy can be used as a pro-survival mechanism by those 
breast cancer cells with decreased level of functional Cav-1 and impaired lipid 
rafts, which providing a possible explanation for the poor clinical outcomes of 
those breast cancer patients with Cav-1 deficiency (Ma et al., 2013b; Sloan et 
al., 2009; Witkiewicz et al., 2010).  
Inhibition of autophagy becomes one novel approach in cancer therapy, 
including combinational therapy with other established cancer therapeutic 
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agents (Kimura et al., 2013; White, 2012; White and DiPaola, 2009). However, 
at present, there is no reported biomarker in selection of cancer patients for 
autophagy-targeted chemotherapies. Thus, our study indicates that those breast 
cancer patients with Cav-1 deficiency might be more applicable to autophagy 
inhibitors in cancer chemotherapy.  
 
6.4. CONCLUSIONS AND FUTURE RESEARCH 
As shown in Figure 6.3, in this study, the function of Cav-1 and lipid rafts in 
autophagy modulation has been systematically investigated. This study 
consists of the following three parts: (i) Cav-1 deficiency and lipid rafts 
disruption enhance autophagy at early stage via promotion of autophagosome 
biogenesis; (ii) Cav-1 deficiency and lipid rafts disruption enhance autophagy 
via promoting lysosomal function at late stage; (iii) autophagy mediated by 
Cav-1 deficiency and lipid rafts disruption plays a pro-survival role and 
supports breast cancer development. The main findings are:  
1. Cav-1 deficiency and disruption of lipid rafts by cholesterol depletion drug 
MBCD increase both basal and inducible autophagic flux.  
     a) This effect is dependent on planar lipid rafts which containing Cav-1 
protein. 
     b) The induction of autophagy after lipid rafts disruption is independent of 
the Akt-mTOR pathway 
2. Disruption of lipid rafts promotes autophagosome formation via VAMP7 
protein. 
      a) Disruption of lipid rafts promotes the mobility of Atg16L1 vesicles, and 
enhances Atg5-Atg12 conjugation and autophagosome formation.  
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      b) The interactions between SNARE protein VAMP7 and the autophagic 
proteins (Atg5 and LC3) increase after lipid rafts disruption 
      c) The colocalization between VAMP7 and lipid rafts maker decreases 
after lipid rafts disruption and amino acid starvation.  
3. The lysosomal function is enhanced by lipid rafts disruption and Cav-1 
deficiency.  
         a) Lipid rafts and Cav-1 present in lysosome membrane. 
         b) Disruption of lipid rafts promotes lysosomal V-ATPase assembly. 
          c) V-ATPase V0 subunits interact with Cav-1 directly. 
          d) Lipid rafts disruption and amino acid starvation decrease interaction 
between Cav-1 and V-ATPase V0 subunits.  
4. Lipid rafts disruption-mediated autophagy serves as a cell survival 
mechanism under starvation to provide survival advantages for breast cancer. 
        a) Autophagy mediated by Cav-1 deficiency and lipid rafts disruption 
promotes cell survival under starvation. 
        b) Lipid rafts and Cav-1 level is down-regulated in several breast cancer 
cell lines. 
        c) A decreased Cav-1 level and increased autophagy level is found in 
breast cancerous tissues. 
Taken together, as shown in Figure 6.3, our data have demonstrated that Cav-1 
and lipid rafts are closely implicated in determining cell stress responses via 
regulation of autophagy in both early and late stage, and this survival 
advantages can be used by breast tumor cells against stress conditions. We 
believe that data from this study contribute to the current knowledge for the 
function of Cav-1 and lipid rafts in autophagy regulation. Therefore, our study 
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not only expands the functional scope of Cav-1 and lipid rafts, but also 
provides a foundation for development of novel clinical indicator for the 
suitability of using autophagy suppression as a therapeutic strategy for the 
patients with down-regulated Cav-1 in breast tumor cells. 
 
Figure 6.3 Model of the regulatory roles of lipid rafts and Cav-1 in 
autophagy, cellular stress response and tumorigenesis.  
 
This study provides the evidence supporting a suppressive regulatory roles of 
lipid rafts and Cav-1 in autophagy, cellular stress response in breast cancer 
cells. Thus, our study suggests Cav-1 can be considered as a indicator for 
using autophagy inhibitors in therapeutic strategy. To translate this strategy 
obtained from experiments performed in in vitro cell culture system and 
human tissue samples to human with beneficial pharmacological effects, the in 
vivo nude mice xenograft model should be performed in the future. It should 
be interesting to know the therapeutic efficacy of autophagy inhibitors (such 
as hydroxychloroquine (HCQ)) on breast tumor cells with different Cav-1 
expression level nude mice xenograft model. Such data will provide strong 
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evidence to suggest the suitability of those human breast cancer cells with 
deficient or lower Cav-1 expression for autophagy inhibition strategy. 
In addition, for the mechanistic study, to further understand how the lipid rafts 
and Cav-1 regulate the autophagy events, several obstacles need to be 
overcome. In this study, the SNAREs proteins, especially VAMP7, are found 
to be critical for the suppressive role of Cav-1 and lipid rafts on the 
autophagosome formation in the early stage of autophagy. However, the exact 
molecular mechanism underlying the regulatory function of lipid rafts on 
VAMP7 still needs to be further studied. The involvements of other SNAREs 
protein, such as Syntaxin 17 or VAMP8, also remain to be further confirmed. 
What's more, in the late stage of autophagy, lipid rafts and Cav-1 are proved to 
be associated with V-ATPase V0 subunits and suppress their assembly ability 
with V1 subunits, which is critical for maintaining the acidic environment of 
lysosomal degradation. But the exact binding site of Cav-1 and V-ATPase V0 
subunits and why disruption of lipid rafts by MBCD treatment will disturb this 
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